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Abstract
The results from Genome-Wide Association Studies (GWAS) on thousands of
phenotypes provide an unprecedented opportunity to infer the causal effect of one
phenotype (exposure) on another (outcome). Mendelian randomization (MR), an
instrumental variable (IV) method, has been introduced for causal inference using
GWAS data. Due to the polygenic architecture of complex traits/diseases and the
ubiquity of pleiotropy, however, MR has many unique challenges compared to con-
ventional IV methods. We propose a Bayesian weighted Mendelian randomization
(BWMR) for causal inference to address these challenges. In our BWMR model, the
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uncertainty of weak effects owing to polygenicity has been taken into account and
the violation of IV assumption due to pleiotropy has been addressed through outlier
detection by Bayesian weighting. To make the causal inference based on BWMR com-
putationally stable and efficient, we developed a variational expectation-maximization
(VEM) algorithm. Moreover, we have also derived an exact closed-form formula to
correct the posterior covariance which is often underestimated in variational infer-
ence. Through comprehensive simulation studies, we evaluated the performance of
BWMR, demonstrating the advantage of BWMR over its competitors. Then we
applied BWMR to make causal inference between 130 metabolites and 93 complex
human traits, uncovering novel causal relationship between exposure and outcome
traits. The BWMR software is available at https://github.com/jiazhao97/BWMR
Keywords: Mendelian randomization; Causal inference; GWAS; Summary Statistics
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1 Introduction
Determination of the causal effect of a risk factor (exposure) on a complex trait or disease
(outcome) is critical for health management and medical intervention. Random controlled
trial (RCT) is often considered as the golden standard for causal inference. When the
evidence from RCT is lacking, Mendelian Randomization (MR) (Katan, 1986; Evans and
Davey Smith, 2015) was proposed to mimic RCT using natural genetic variations for causal
inference. The idea is that the genotypes are randomly assigned from one generation to next
generation according to Mendelian Laws of Inheritance. Therefore, genotypes which should
be unrelated to confounding factors can serve as instrumental variables (IVs) (Lawlor et al.,
2008; Baiocchi et al., 2014), helping to eliminate the possibility of reverse causality.
In recent years, MR becomes more and more popular because Genome-Wide Asso-
ciation Studies (GWAS) have been performed on thousands of phenotypes. In particu-
lar, summary statistics from GWAS are available through public gateways (e.g., https:
//www.ebi.ac.uk/gwas/downloads/summary-statistics). These data sets contain very
rich information, such as reference allele frequency of single nucleotide polymorphisms
(SNPs), the effect size of a SNP on the phenotype and its standard error, such that MR
can be performed without accessing individual-level GWAS data.
From the statistical point of view, MR can be viewed as an instrumental variable
method. However, due to the complexity of human genetics (e.g., polygenicity (Visscher
et al., 2017), pleiotropy (Solovieff et al., 2013; Yang et al., 2015) and linkage disequilib-
rium (LD) in human genome (The 1000 Genomes Project Consortium et al., 2012) and
complicated data processing and sharing (e.g., sample overlap in multiple GWAS), MR has
several unique challenges compared with conventional IV methods. First, in the presence
of polygenic architecture, there exist many weak SNP-exposure effects rather than strong
effects only. The uncertainty of estimated weak effects needs to be taken into account.
Second, based on current GWAS results, it is often observed that a SNP can affect both
exposure and outcome traits. This phenomenon is referred as “pleiotropy” or “horizontal
pleiotropy”. The ubiquity of horizontal pleiotropy easily makes the assumption in classical
IV methods invalid, resulting in many false positives if horizontal pleiotropy is not taken
into account. Third, a number of potential risks may be involved in summary statistics-
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based MR, such as, different LD patterns in exposure and outcome traits, selection bias of
SNP-exposure effects and other bias due to overlapped samples.
To address these challenges, much efforts have been devoted in MR recently. To name
a few, PRESSO has been proposed to handle horizontal pleiotropy (Verbanck et al., 2018).
A sampling strategy is used in PRESSO to detect outliers due to horizontal pleiotropy and
then inverse variance weighted (IVW) regression (Burgess et al., 2013) is applied to estimate
causal effects. However, estimation uncertainty of SNP-exposure effects is ignored in the
PRESSO model. It is also not computationally efficient owing to the sampling strategy. By
assuming that horizontal pleiotropic effects are unknown constant, Egger (Bowden et al.,
2015) extends the IVW method by introducing an additional intercept term. Despite this
improvement over IVW, Egger suffers from high estimation error in presence of many weak
horizontal pleiotropic effects as its assumption fails in this situation. Moreover, Egger
would be biased when there exist a few large pleiotropic effects (i.e., outliers). GSMR
(Zhu et al., 2018) improves existing methods by introducing outlier detection to remove
the influence of large pleiotropic effects and take the linkage disequilibrium between IVs
into account. However, GSMR adopts an ad-hoc outlier detection procedure and it does
not take weak pleiotropic effects into consideration. Therefore, its type I error rate can
be inflated in real data analysis. RAPS is a newly developed method (Zhao et al., 2018),
aiming to improve statistical power for causal inference by including weak effects in GWAS
and removing outliers due to horizontal pleiotropy. Although the theoretical property of
RAPS has been established, its accompanying algorithm is numerically unstable, resulting
in unreliable estimated causal effects (see our experimental results in supplementary Figs.
43-45).
In this paper, we propose a method named ‘Bayesian Weighted Mendelian Random-
ization (BMWR)’ for causal inference using summary statistics from GWAS. In BWMR,
uncertainty of estimated weak effects in GWAS and influence of horizontal pleiotropy have
been addressed in a unified statistical framework. To make BWMR computationally effi-
cient and stable, we developed a variational expectation-maximization algorithm to infer
the posterior mean of the causal effects. Importantly, we further derived an exact closed-
form formula to correct the posterior covariance which was often underestimated in varia-
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tional inference. Through comprehensive simulation studies, we showed that BMWR was
computationally stable and statistically efficient, compared to existing related methods.
Then we applied BWMR to real data analysis, further demonstrating the statistical prop-
erties of BWMR and revealing novel causal relationships between exposure and outcome
traits.
2 Methods
2.1 Model
We primarily focus on estimating the causal effect of an exposure X on an outcome Y with
unknown confounding factors U in the framework of MR. To perform the standard MR,
an instrumental variable method for causal inference, the following three criteria ensuring
the validity of IVs should be satisfied:
• Relevance criterion: IVs are associated with the exposure X.
• Effective random assignment criterion: IVs are independent of confounders U .
• Exclusion restriction criterion: IVs only affect the outcome Y through the exposure
X.
Assuming the validity of IVs, we begin with the following linear model for MR:
X =
N∑
j=1
γjGj + ηXU + X , Y = βX + ηYU + Y , (1)
where Gj (j = 1, 2, ..., N) are independent SNPs serving as IVs, γj (j = 1, 2, ..., N) are
SNP-exposure effects, ηX and ηY are effects of confounders U on exposure X and outcome
Y , X and Y are independent error terms, i.e., (X , Y ) |= (G1, G2, ..., GN , U), X |= Y , and
β denotes the causal effect of interest. Eq. (1) implies
Y =
N∑
j=1
βγjGj + (βηx + ηy)U + βx + y. (2)
Let Γj be the effect of Gj on outcome Y . From Eq. (2), we have
Γj = βγj, j = 1, 2, ..., N. (3)
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This equation implies that we can estimate β based on Γj and γj.
In practice, we do not know Γj and γj, but have their estimates from summary statis-
tics of GWAS. Let {γˆj, σXj , pXj} and {Γˆj, σYj , pYj} be estimated effect sizes of Gj, standard
errors and p-values for both exposure X and outcome Y , respectively. Because of the
large sample size of GWAS, we ignore the uncertainty in estimating σXj , σYj . To ensure
the relevance criterion, we first select SNPs which are significantly associated with expo-
sure X (e.g., pXj ≤ 5 × 10−8). We further apply LD clumping to those selected SNPs
to ensure the independence of IVs (Purcell et al., 2007). The remaining summary statis-
tics are denoted as D = {γˆ, Γˆ,σX ,σY } serving as the input data of our model, where
γˆ = (γˆ1, ..., γˆN), Γˆ = (Γˆ1, ..., ΓˆN),σX = (σX1 , ..., σXN ),σY = (σY1 , ..., σYN ). Note that the
relationship between estimated effect sizes and the corresponding true effect sizes is given
in the following probabilistic model:
γˆj|γj ∼ N (γj, σ2Xj), Γˆj|Γj ∼ N (Γj, σ2Yj), j = 1, 2, ..., N. (4)
According to Mendel’s Law, it is also reasonable to assume that effective random assignment
criterion is satisfied in real-data application. However, the exclusion restriction criterion
does not often hold because of the ubiquity of horizontal pleitropy (i.e., IVs may have direct
effects on outcome Y ).
To address this challenge, we notice that Eq. (3) can be relaxed as
Γj = βγj + αj, j = 1, 2, ..., N, (5)
by assuming that
αj
i.i.d.∼ N (0, τ 2), (α1, α2, .., αN) |= (γ1, γ2, ..., γN), (6)
where τ 2 is an unknown parameter to be estimated from data. In such a way, estimating β
from Eq. (5) can be viewed as a noisy version of estimation from Eq. (3), where α1, . . . , αN
are viewed with independent random noise. In fact, the linear model corresponding to Eq.
(5) is
X =
N∑
j=1
γjGj + ηXU + X , Y = βX +
N∑
j=1
αjGj + ηYU + Y . (7)
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The presence of term αjGj indicates that the exclusion restriction criterion can be relaxed
as long as the direct effect αj satisfies (6). The nonzero variance τ
2 naturally accounts for
the influence of weak pleiotropic effects αj, j = 1, . . . , N .
Combining Eqs. (4,5,6), we have
γˆj|γj ∼ N (γj, σ2Xj), Γˆj|β, γj ∼ N (βγj, σ2Yj + τ 2). (8)
If we treat γj (j = 1, . . . , N) as model parameters, then the number of model parameters is
going to increase as the number of samples {γˆj, Γˆj} increases. Therefore, we assign a prior
distribution on γj,
γj
i.i.d.∼ N (0, σ2), (9)
with an unknown parameter σ2 to be estimated from data. To facilitate statistical inference
in Bayesian framework, we also assign a non-informative prior on β
β ∼ N (0, σ20). (10)
When σ0 → ∞, the result from Bayesian inference on β will naturally converge to the
inference result based on maximum likelihood estimation. Let γ be the collection of
{γ1, . . . , γN}. Combining Eq. (8) with Eq. (9) and Eq. (10), our probabilistic model
becomes
p(γˆ, Γˆ, β,γ|σ2X ,σ2Y , τ 2, σ2, σ20)
=N (β|0, σ20)
N∏
j=1
N (γj|0, σ2)
N∏
j=1
N (γˆj|γj, σ2Xj)
N∏
j=1
N (Γˆj|βγj, σ2Yj + τ 2).
(11)
In the presence of strong horizontal pleiotropy, the direct effect αj in Eq. (7) may
become extremely large and thus it does not satisfy Eq. (6). To ensure that our model
works well in this case, we cast those αj as outliers. As inspired by reweighed probabilistic
models (Wang et al., 2016), here we propose a strategy to guarantee the robustness of the
above model. Let w = [w1, . . . , wN ], where wj ∈ {0, 1} is the weight corresponding to
the j-th observation. We would like to assign wj = 0 if αj deviates from model (11), and
wj = 1 otherwise. With this consideration, we assume
wj|pi1 i.i.d.∼ Bernoulli(pi1), pi1 ∼ Beta(a0, 1),
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where a0 is specified as 100 throughout this paper, preferring there is a small proportion
of outliers. Then we reformulate model (11) as
p(γˆ, Γˆ, β, pi1,γ,w|σ2X ,σ2Y , τ 2, σ2, σ20, a0)
=
1
A
N (β|0, σ20) Pr(pi1|a0)
N∏
j=1
N (γj|0, σ2)
N∏
j=1
Pr(wj|pi1)
N∏
j=1
N (γˆj|γj, σ2Xj)
N∏
j=1
N (Γˆj|βγj, σ2Yj + τ 2)wj .
(12)
where A is the normalization constant to ensure (12) is a valid probability model.
To sum up, we refer to our model (12) as Bayesian Weighted Mendelian Randomization
(BWMR). BWMR takes summary statistics D = {γˆ, Γˆ,σX ,σY } as its input, aiming to
provide the posterior mean and variance on causal effect β, in which z = {β, pi1,w,γ} is
the collection of latent variables, θ = {τ 2, σ2} is the set of the model parameters to be
optimized, and h0 = {σ0 = 1× 106, a0 = 100} is the collection of fixed hyper-parameters.
2.2 Algorithm
To provide accurate statistical inference, we are interested in posterior distribution of the
latent variables:
p(z|D,θ,h0) = p(γˆ, Γˆ, z|σ
2
X ,σ
2
Y ,θ,h0)
p(γˆ, Γˆ|σ2X ,σ2Y ,θ,h0)
,
where
p(γˆ, Γˆ|σ2X ,σ2Y ,θ,h0) =
∫
z
p(γˆ, Γˆ, z|σ2X ,σ2Y ,θ,h0)dz.
However, exact evaluation of the posterior distribution is very challenging because the
integration is intractable.
Instead, we propose a variational expectation-maximization (VEM) algorithm to ap-
proximate the posterior. Let q(z) be a variational distribution. The logarithm of the
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marginal likelihood can be written as
log p(γˆ, Γˆ|σ2X ,σ2Y ,θ,h0)
= Eq(z)[log p(γˆ, Γˆ|σ2X ,σ2Y ,θ,h0)]
= Eq(z)
[
log
p(γˆ, Γˆ, z|σ2X ,σ2Y ,θ,h0)
q(z)
+ log
q(z)
p(z|D,θ,h0)
]
= L(q,θ) +KL(q(z)‖p(z|D,θ,h0)),
where
L(q;θ) := Eq(z)
[
log
p(γˆ, Γˆ, z|σ2X ,σ2Y ,θ,h0)
q(z)
]
,
KL(q(z)‖p(z|D,θ,h0)) = Eq(z)
[
log
q(z)
p(z|D,θ,h0)
]
.
Given that the Kullback-Leibler (KL) divergence KL(·‖·) is non-negative, L(q;θ) is an
evidence lower bound (ELBO) of marginal likelihood. Thus, maximization of ELBO L(q;θ)
w.r.t. variational distribution q and parameters θ is commonly referred to as E-step and M-
step: In the E-step, variational distribution q is updated to approximate the true posterior
distribution. In the M-step, the set of model parameters θ is optimized to increase EBLO
and thus increase the marginal likelihood.
We adopt mean-field variational Bayes (MFVB) and assume that q(z;η) can be factor-
ized as
q(z;η) = q(β;η)q(pi1;η)
N∏
j=1
q(γj;η)
N∏
j=1
q(wj;η).
where η collects all the variational parameters. Without further assuming any specific
forms of the variational distributions, the optimal variational distributions in the E-step
can be obtained naturally as
q(β|µβ, σ2β) = N (β|µβ, σ2β), q(γ|{µγj , σ2γj}) =
N∏
j=1
N (γj|µγj , σ2γj),
q(w|piwj) = Bernoulli(wj|{piwj}), q(pi1|a, b) = Beta(pi1|a, b),
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with the updating equations
σ2β =
[
1
σ20
+
N∑
j=1
piwj(µ
2
γj
+ σ2γj)
σ2Yj + τ
2
]−1
µβ =
(
N∑
j=1
piwjµγj Γˆj
σ2Yj + τ
2
)
σ2β,
σ2γj =
[
1
σ2Xj
+
piwj(µ
2
β + σ
2
β)
σ2Yj + τ
2
+
1
σ2
]−1
,
µγj =
(
γˆj
σ2Xj
+
piwjµβΓˆj
σ2Yj + τ
2
)
σ2γj ,
a =a0 +
N∑
j=1
piwj , b = N + 1−
N∑
j=1
piwj , piwj =
qj1
qj0 + qj1
,
qj0 = exp[ψ(b)− ψ(a+ b)],
qj1 = exp
[
− log(2pi)
2
− log(σ
2
Yj
+ τ 2)
2
+ ψ(a)− ψ(a+ b)
]
+ exp
[
−(µ
2
β + σ
2
β)(µ
2
γj
+ σ2γj)− 2µβµγj Γˆj + Γˆ2j
2(σ2Yj + τ
2)
]
,
where variational parameters are collected in
η = {µβ, σ2β; a, b; {µγj , σ2γj}Nj=1; {piwj}Nj=1},
and ψ(·) represents the digamma function. In the M-step, by setting the derivative of
ELBO w.r.t. σ2 to zero, the updating equation for σ2 can be easily obtained as
σ2 =
N∑
j=1
(µ2γj + σ
2
γj
)/N.
Derivation of the updating equation for τ 2 is much more technical. We have made use of
a number of tricks in convex optimization and obtain a closed-form updating equation for
τ 2 as
τ2 =
√√√√√√√√√
N∑
j=1
piwj [(µ
2
β + σ
2
β)(µ
2
γj
+ σ2γj )− 2µβµγj Γˆj + Γˆ2j ](τ (old)))4
[σ2Yj
+ (τ (old)))2]2
N∑
j=1
piwj
σ2
Yj
+(τ(old))2
,
where (τ (old)))2 is the estimate of τ 2 at previous iteration. Importantly, all updating
approaches in VEM algorithm have closed-forms, ensuring the efficiency and stability of
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our proposed algorithm. The details of the above derivation are given in the supplementary
document. After convergence of the VEM algorithm, we can obtain the set of optimized
variational parameters η∗ and the set of estimated model parameters θˆ. The posterior mean
of β has been naturally given by µ∗β, which is very accurate as shown later. However, the
posterior variance of β given by MFVB, i.e., (σ2β)
∗, often underestimates the true posterior
variance. We address this issue in next section.
2.3 Inference
As inspired by the linear response methods (Giordano et al., 2015, 2018), we propose a
closed-from formula to correct the underestimated posterior variance, yielding an accurate
inference for β.
For notation convenience, we denote p0(z) as the true posterior of interest. We define
a perturbation of the true posterior as
pt(z) := p0(z) exp(tβ − C(t)),
where t is a scalar and C(t) normalizes pt(z). When t = 0, pt(z) becomes the unperturbed
posterior p0(z). Clearly, pt(z) forms an exponential family parameterized by t. By the
property of the cumulant generating function of exponential families, we have
Ept [β] =
dC(t)
dt
, Varpt [β] =
d2C(t)
dt2
,
implying that the posterior variance of β can be written as
Varp0 [β] =
dEpt [β]
dt
∣∣∣∣
t=0
. (13)
This implies that the sensitivity of posterior mean at t = 0 can provide information about
the true posterior variance.
Now we introduce the key idea to approximate the posterior variance in Eq. (13)
from MFVB. Let qt(z) be the mean-field approximation to pt(z), i.e., qt(z) := q(z;η
∗
t ) =
arg minqKL(q(z;η)||pt(z)). Since MFVB often provides accurate inference on posterior
mean (Blei et al., 2017), we assume the following conditions hold:
Condition 1: Eqt [β] ≈ Ept [β] for all t, and
Condition 2:
dEqt [β]
dt
∣∣∣
t=0
≈ Ept [β]
dt
∣∣∣
t=0
.
(14)
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Condition 1 says that MFVB can provide good approximations to posterior means of all the
perturbations. Condition 2 further requires the accuracy of the first order approximation
at t = 0. As we shall show in the supplementary document, the following equation holds:
dEqt [β]
dt
∣∣∣
t=0
= −gTH−1g, (15)
where
g =
dEq(z;η)[β]
dηT
∣∣∣∣
η=η∗0
, H =
∂L(q,θ)
∂η∂ηT
∣∣∣∣
η=η∗0
with η∗0 being the set of optimal variational parameters obtained at t = 0. Note that η
∗
0
is exactly the parameter set η∗ obtained by the MFVB algorithm in Section 2.2. Con-
sequently, combining Eqs. (13,14,15), the posterior variance of β can be approximated
by
Varp0 [β] =
dEpt [β]
dt
∣∣∣∣
t=0
≈ dEqt [β]
dt
∣∣∣∣
t=0
= −gTH−1g.
To provide statistical inference on β as what many MR methods offered, we specify σ0 in
Eq. (10) as 1×106 throughout this paper. In such a way, BWMR can provide the estimate
of β using µ∗β, its standard error using
√
Varp0 [β] and corresponding p-value. We shall
use simulation study to evaluate whether the above proposed method indeed provides an
accurate inference.
3 Results
3.1 Simulation study
To closely mimic real data analysis, we simulated individual-level data, and then obtained
(γˆj, σXj , pXj) and (Γˆj, σYj , pYj) by simple linear regression. We also included the IVs selec-
tion procedure in the simulation study to investigate the potential effect of selection bias.
Let G1 ∈ Rn1×N0 and G2 ∈ Rn2×N0 be the individual-level genotype data for exposure X
and outcome Y , where N0 was the number of genotyped SNPs, n1 and n2 were sample
sizes of exposure data and outcome data, respectively. The columns of G1 and G2 were
generated independently such that these independent SNPs could serve as IVs. The minor
allele frequencies of the SNPs were drawn from the uniform distribution U [0.05, 0.5]. The
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vectors of effect sizes γ and Γ = βγ + α were simulated based on a four-group model
(Chung et al., 2014) to investigate the influence of horizontal pleiotropy. Let G00,G10,G01,
and G11 denote these four groups of SNPs, and pi00, pi10, pi01 and pi11 denote the proportions
of SNPs in these four groups, respectively. The four groups of SNPs were given as follows.
• In G00, the SNPs affected neither exposure X nor outcome Y , i.e., γj = 0, αj = 0.
The SNPs in this group were irrelevant, serving as noise IVs.
• In G10, the SNPs affected exposure X only, i.e., γj 6= 0 and αj = 0. The SNPs
included in this group served as valid IVs in the framework of MR.
• In G01, the SNPs affected outcome Y only, i.e., γj = 0 and αj 6= 0. The SNPs in this
group are noise IVs.
• In G11, the SNPs directly affected both exposure X and outcome Y , i.e., γj, αj 6= 0.
This group was used to mimic the phenomenon of horizontal pleiotropy. The SNPs
in this group could be selected as IVs, but they were actually invalid.
For nonzero γj and αj, they were simulated from N (0, σ2γ) and N (0, σ2α). Given the vectors
of effect sizes, we generated the vectors of phenotypes as x = G1γ + ε1 and y = G2Γ +
ε2, where ε1 and ε2 were independent noises from N (0, σ21) and N (0, σ22), respectively.
To evaluate the type I error and statistical power of different methods, we varied β ∈
{0.0, 0.1, 0.2, 0.3, 0.4, 0.5} and group proportions {pi00, pi10, pi01, pi11} while controlled the two
signal-noise-ratios (SNR1 :=
√
Var(G1γ)/Var(ε1) and SNR2 :=
√
Var(G2Γ)/Var(ε2)) at
1:1 by specifying the variance parameters {σ2γ, σ2α, σ21 , σ22}. Throughout the simulation
study, we set sample sizes for exposure and outcome data as n1 = n2 = 5, 000 and the
number of total SNPs as N0 = 10, 000.
With individual-level data {G1,G2,x,y}, we obtained the summary-level statistics
γˆj, Γˆj, with their standard errors σXj , σYj and p-values pXj , pYj , j = 1, 2, ..., N0, by regress-
ing x on each column of G1 and y on each column of G2, respectively. Then we selected
SNPs as IVs if their p-values were smaller than a given threshold at 1× 10−5. As a result,
the input data set for four MR methods (i.e., BWMR, Egger, GSMR, and RAPS) was
given as D = {γˆj, σ2Xj , Γˆj, σYj |pXj ≤ 1× 10−5}. In our simulation study, we observed that
all the MR methods gave biased estimates of β (see results in Fig. 24 of the supplementary
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document). In fact, this phenomenon should be attributed to winner’s curse in the context
of GWAS (Zhong and Prentice, 2008) or selection bias in statistical literature (Efron, 2011).
Briefly speaking, γˆj in the input data set D is selected based on pXj ≤ 1× 10−5, and thus
E[γˆj|γj; pXj ≤ 1× 10−5] 6= E[γˆj|γj] = γj, i.e., the extracted effect size γˆj would be a biased
estimate of γj due to the selection process (pXj < 1 × 10−5). To avoid selection bias, we
simulated two independent datasets for the exposure (i.e., x = G1γ+ε1 and x˜ = G˜1γ+ ε˜1
with equal sample sizes n1 = n˜1). We used one data set (i.e., {G1,x}) to compute p-values
for SNP selection and used another data set (i.e., {G˜1, x˜}) to extract the corresponding
estimated SNP-exposure effects and its standard error {γˆj, σXj}. In such a way, the issue
of selection bias was avoided in our simulation study.
To investigate the performance of BWMR and three other related MR methods on
the influence of horizontal pleiotropy, we varied the propotion pi11
pi10+pi11
∈ {0.2, 0.5, 0.8},
approximately controlling the proportion of IVs affected by horizontal pleiotropy among
all IVs at 20%, 50%, 80% respectively. We observed that BWMR showed satisfactory
performance in terms of estimation accuracy, type I error control and statistical power, as
shown in Fig. 1. The satisfactory performance of BWMR can be attributed to its following
properties: 1. adaptive use of variance component τ 2 to account for weak pleiotropic
effects; 2. robustness to strong horizontal pleiotropy guaranteed by the Bayesian weighting
scheme; 3. stable and efficient algorithm for parameter estimation and inference. From
the simulation study, we also observed that GSMR seemed to have the highest statistical
power among all the MR methods. However, the p-value of GSMR was also observed to
be inflated in the qq-plot when a higher proportion of IVs (e.g., 50%, 80%) affected by
horizontal pleiotropy (see supplementary Fig. S20). Thus, the type I error rate of GSMR
was unable to be controlled at the nominal level. This is because GSMR ignored the
weak pleiotropic effects and underestimated the standard error of the casual effect. Egger
was found to be the most conservative one among the four MR methods. Its estimation
was observed to have the largest variance because the intercept term introduced in Egger
was unable to model the weak pleiotropic effects which should not be simply treated as a
constant. Among the four MR methods, BWMR and RAPS had similar performance in
this simulation study, but RAPS was found to be numerically not stable in the next real
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data analysis part. To have a better understanding of the four MR methods, we provided
a detailed discussion about their relationship in the supplementary document (see our
supplementary note). To make the simulation results easily reproducible, we have made
the code of our simulation study available at https://github.com/jiazhao97/sim-BWMR.
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Figure 1: Comparison of MR methods affected by horizontal pleiotropy (the propor-
tions of horizontal pleiotropic IVs were specified as pi11
pi10+pi11
= 20%, 50%, and 80%, in
the top, middle and bottom panel, respectively). The parameters were chosen to be
N0 = 10, 000, n1 = n2 = 5, 000, β ∈ {0.0, 0.1, 0.2, 0.3, 0.4, 0.5}, SNR1 = SNR2 = 1 : 1,
and p-value threshold = 1× 10−5. We evaluated the empirical type I error rate and power
by controlling type I error rates at the nominal level 0.05. The results were summarized
from 100 replications.
3.2 Real Data Analysis
3.2.1 Materials
To investigate the influence of selection bias on real data analysis and the reliability of the
four MR methods, we collected three different GWASs of four global lipids, i.e., high-density
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lipoprotein (HDL) cholesterol (HDL-C), low-density lipoprotein (LDL) cholesterol (LDL-
C), triglycerides (TG) and total cholesterol (TC). For narrative convenience, we shall refer
them as Data-A (Willer et al., 2013), Data-B (Kettunen et al., 2016) and Data-C (Klarin
et al., 2018) (the details of the three GWASs are given in the supplementary document). It
is worthwhile to note that Data-C only includes SNPs significantly associated with global
lipids.
Besides the four global lipids in Data-A, Data-B, and Data-C, we further collected
GWAS summary statistics, covering 126 metabolites (Kettunen et al., 2016) and 93 human
complex traits. These metabolites include lipoprotein (e.g. very-low-density lipoprotein
(VLDL) and LDL), fasting glucose, Vitamin D levels and serum urate. The 93 human
complex traits include anthropometric traits (e.g. body mass index (BMI)), cardiovascular
measures (e.g. coronary artery disease (CAD)), immune system disorders (e.g. atopic der-
matitis), metabolic traits (e.g. dyslipidemia), neurodegenerative diseases (e.g. Alzheimers
disease (AD)), psychiatric disorders (e.g. bipolar disorder), social traits (e.g. intelligence)
and other complex traits (e.g. breast cancer). The details of summary statistics are given
in the supplementary document.
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Figure 2: Comparisons of analysis results provided by BWMR with selection bias (x-axis)
and without selection bias (y-axis). The dots represent estimated causal effect sizes βˆ and
the bars represent their standard errors se(βˆ). The diagonal is indicated by the dashed
line.
3.2.2 Examination of selection bias
In this subsection, we consider estimating the causal effect β of each of four global lipids
(i.e., HDL-C, LDL-C, TG and TC) on 93 complex traits. Given Data-A and Data-B,
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to avoid potential selection bias, we used one exposure data set (e.g., Data-A) to select
IVs and extracted the corresponding estimated effect sizes and their standard errors in
another exposure data set (e.g., Data-B), i.e., {γˆj, σXj}. Based on the selected IVs, we also
obtained effect sizes and their standard errors from the outcome data sets, i.e., {Γˆj, σYj}.
The analysis based on this type of input data was expected to provide unbiased estimation
results. To investigate selection bias, we selected IVs and extracted the estimated effect
sizes and standard errors using the same data set (e.g., Data-A). Therefore, this type of
input data was expected to suffer from selection bias. We applied BWMR to both unbiased
and biased input data sets, and compared the analysis results to evaluate the influence of
selection bias. The results from BWMR are shown in Fig. 2, and the results from other
three methods are shown in the supplementary Figs. 26, 27 and 28. Although the analysis
results were expected to be different, no systematic discrepancies between biased results
and unbiased results were observed. As we illustrated in simulation study, the influence of
selection bias decreases as the sample size increases (see supplementary Fig. 25). Note that
the sample sizes of Data-A and Data-B are very large (nA = 188, 577 and nB = 24, 925,
respectively). The sample sizes are large enough such that the influence of selection bias
would be ignorable. As a result, we concluded that selection bias might not introduce much
bias when we were analyze the causal effects between those metabolites and complex traits
in this paper.
3.2.3 Consistency of BWMR’s analysis results
Before applying BWMR to infer the causal effects between hundreds of metabolites and
complex traits, we first checked the reliability of BWMR’s analysis results on the four
global lipids. To do so, we explored the third data set, i.e., Data-C, to select IVs, and
then used Data-A and Data-B to extract exposure effect sizes and their standard errors,
denoted as {γˆ(A)j , σ(A)Xj } and {γˆ
(B)
j , σ
(B)
Xj
}, and then extracted the outcome effect sizes and
their standard errors {Γˆj, σYj}. After that, we applied BWMR to {γˆ(A)j , σ(A)Xj , Γˆj, σYj} and
{γˆ(B)j , σ(B)Xj , Γˆj, σYj}. The analysis results are shown in Fig. 3. The results of other three
MR methods are shown in supplementary Figs. 29, 30 and 31. We can see clearly that the
results based on Data-A and Data-B agree well with each other, indicating that estimating
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the causal relationship between metabolites and complex traits by BWMR can be quite
reliable.
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Figure 3: Comparisons of analysis results provided by BWMR using Data-A as exposure
data (x-axis) and using Data-B as exposure data (y-axis). The dots represent estimated
causal effect sizes βˆ and the bars represent their standard errors se(βˆ). The diagonal is
indicated by the dashed line.
3.2.4 MR-based causal inference between metabolites and complex traits
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Figure 4: Left: numbers of significant causal effects of metabolites on complex traits;
Middle Left: numbers of significant causal effects of complex traits on metabolites; Middle
Right: QQ plot of p-values based on estimates of causal effects of metabolites on complex
traits; Right: QQ plot of p-values based on estimates of causal effects of complex traits on
metabolites.
After carefully examining the selection bias issue and consistency of four MR methods,
it is ready for us to apply BWMR and the other three MR methods to estimate: (a) the
causal effects of metabolites on complex human traits, and (b) the causal effects of complex
traits on metabolites. The analysis results are summarized in supplementary Figs. 37-49.
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We observed a protective effect of HDL-C against the trait dyslipidemia (βˆ = −0.20,
p-value = 1.36 × 10−5), and positive effects of LDL-C (βˆ = 0.62, p-value = 2.64 × 10−128)
and TG (βˆ = 0.37, p-value = 1.26 × 10−22) on dyslipidemia. Note that the diagnostic
criterion for dyslipidemia includes abnormally low level of HDL-C and abnormally high
levels of LDL-C and / or TG (Teramoto et al., 2007). Our observations are consistent with
the diagnostic criterion, indicating the reliability of our real data analysis results.
Besides those identified significant causal effects between metabolites and dyslipidemia,
we identified 46, 101 significant associations based on Bonferroni correction at level 0.05 in
(a), (b) respectively. Among these significant findings, some previous research outcomes are
successfully replicated in our analysis. For example, we observed LDL-C had a significant
risk effect on CAD (βˆ = 0.13, p-value = 1.90 × 10−25) as confirmed by RCTs (Ference
et al., 2017). Similarly, positive causal effects of metabolites included in the class of HDL
on CAD were also observed. Serum urate was found to have a positive causal effect on
gout (βˆ = 0.27, p-value = 1.49 × 10−36), supporting the result of a previous individual
participant data analysis (Dalbeth et al., 2018). Importantly, our results also provided
several new insights. For example, we found AD positively affected 47 metabolites (e.g.,
apoB, metabolites included in LDL and VLDL). As expected, the effect of AD on HDL-C
was opposite to its corresponding effect on LDL-C, i.e., a negative effect of AD on HDL-C
(βˆ = −0.13, p-value = 9.34×10−6) was identified. We also observed significant causal effects
of BMI on 37 metabolites, including 30 positive effects (e.g., effects on TG, serum urate, and
metabolites included in VLVL) and seven negative effects on metabolites included in HDL.
Interestingly, although AD and BMI were found to significantly affect many metabolites,
no metabolites were observed to have causal effects on AD or BMI. Additionally, we found
that glycated hemoglobin levels had positive effects on TC (βˆ = 0.22, p-value = 4.93×10−6)
and LDL-C (βˆ = 0.19, p-value = 1.01× 10−5). On the contrary, height was found to have
negative effects on TC (βˆ = −0.07, p-value = 2.16 × 10−10) and LDL-C (βˆ = −0.05,
p-value = 2.29× 10−7).
To have a better understanding of the statistical properties of four MR methods, we
compared the numbers of causal associations identified by four MR methods after Bonfer-
roni correction, and conducted qq-plots for p-value from the four methods, displayed in Fig.
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4. Consistent with our simulation study, the power of GSMR seems to be the highest among
the four MR methods. As we explained in simulation, the high power of GSMR comes along
with an expensive price, that is, its type I error rate can not be controlled at the nominal
level. To be more specific, we offered real data illustrative examples in supplementary Figs.
32, 30. As we can see more clearly, the inflated type I error of GSMR can be attributed to
the ignored weak pleiotropic effects and the ad-hoc procedure for outlier detection. Egger
was observed to have the lowest statistical power among the four methods. Although the
intercept term may help to correct for the bias caused by horizontal pleiotropic effects,
the presence of weak pleiotropic effects leads to a large variance of Egger’s estimation. In
addition, we found that Egger was not robust to large pleiotropic effects (i.e., outliers), and
would suffer from improper outlier detection as shown in supplementary Figs. 34 and 35.
It seems that the results of BWMR and RAPS are quite similar to each other. However,
we found RAPS was numerically unstable in real data analysis (see supplementary Figs.
43-45), while BWMR provided stable estimates.
4 Conclusion
We have introduced a statistical approach, BWMR, for causal inference based on summary
statistics from GWAS. BWMR can not only accounts for the uncertainty of estimated weak
effects and weak horizontal pleiotropic effects, but also adaptively detect outliers due to a
few large horizontal pleiotropic effects. Through comprehensive simulations and real data
analysis, BWMR is shown to be statistically efficient and computationally stable. As more
summary data will become publicly available, BWMR is believed to be of widely use in the
future.
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SUPPLEMENTARY MATERIAL
Supplementary Document.pdf The document includes the detailed derivation of the
algorithm for BWMR, comparison of MR methods, more simulation results, sources
of GWAS summary statistics datasets used in the this paper, and more real data
analysis results. (PDF)
R-package for BWMR R-package ’BWMR’. The package containing the functions used
in BWMR and an example of applying BWMR to real data is available at https:
//github.com/jiazhao97/BWMR.
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Supplementary Document
A The variational EM algorithm
Let D = {γˆ, Γˆ,σX ,σY } denote the summary statistics serving as the input data, z =
{β, pi1,w,γ} be the collection of latent variables, θ = {τ 2, σ2} be the set of the model
parameters to be optimized and h0 = {σ0 = 1 × 106, a0 = 100} be the collection of fixed
hyparameters. Then according to BWMR, the logarithm of complete-data likelihood is
given as
log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ,θ,h0)
=
N∑
j=1
[
− log(σ
2
Xj
)
2
− (γˆj − γj)
2
2σ2Xj
]
+
N∑
j=1
wj
[
− log(2pi)
2
− log(σ
2
Yj
+ τ 2)
2
− (Γˆj − βγj)
2
2(σ2Yj + τ
2)
]
− β
2
2σ20
+
N∑
j=1
[
− log(σ
2)
2
− γ
2
j
2σ2
]
+
N∑
j=1
[wj log(pi1) + (1− wj) log(1− pi1)]
+ (a0 − 1) log(pi1) + constant.
To provide accurate statistical inference, we are interested in posterior distribution of the
latent variables:
Pr(z|D,θ,h0) = Pr(γˆ, Γˆ, z|σ
2
X ,σ
2
Y ,θ,h0)
Pr(γˆ, Γˆ|σ2X ,σ2Y ,θ,h0)
,
where
Pr(γˆ, Γˆ|σ2X ,σ2Y ,θ,h0) =
∫
z
Pr(γˆ, Γˆ, z|σ2X ,σ2Y ,θ,h0)dz.
However, exact evaluation of the posterior distribution is very challenging because the
integration is intractable.
Instead, we propose a variational expectation-maximization (VEM) algorithm to ap-
proximate the posterior. Let q(z) be a variational distribution. The logarithm of the
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marginal likelihood can be written as
log Pr(γˆ, Γˆ|σ2X ,σ2Y ,θ,h0)
= Eq(z)[log Pr(γˆ, Γˆ|σ2X ,σ2Y ,θ,h0)]
= Eq(z)
[
log
Pr(γˆ, Γˆ, z|σ2X ,σ2Y ,θ,h0)
q(z)
+ log
q(z)
Pr(z|D,θ,h0)
]
= L(q,θ) + DKL(q(z)‖Pr(z|D,θ,h0)),
where
L(q,θ) := Eq(z)
[
log
Pr(γˆ, Γˆ, z|σ2X ,σ2Y ,θ,h0)
q(z)
]
,
DKL(q(z)‖Pr(z|D,θ,h0)) = Eq(z)
[
log
q(z)
Pr(z|D,θ,h0)
]
.
Given that the Kullback-Leibler (KL) divergence DKL(·‖·) is non-negative, L(q;θ) is an
evidence lower bound (ELBO) of marginal likelihood. Thus, maximization of ELBO L(q;θ)
w.r.t. variational distribution q and parameters θ is commonly referred to as E-step and M-
step: In the E-step, variational distribution q is updated to approximate the true posterior
distribution. In the M-step, the set of model parameters θ is optimized to increase EBLO
and thus increase the marginal likelihood.
A.1 E-step
We adopt mean-field variational Bayes (MFVB) and assume that q(z) can be factorized as
q(z) = q(β)q(pi1)
N∏
j=1
q(γj)
N∏
j=1
q(wj).
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Then to optimize ELBO L(q,θ) w.r.t. q(β), we re-arrange it into the terms with and
without q(β):
L(q,θ)
=Eq(z)
[
log
Pr(γˆ, Γˆ, z|σ2X ,σ2Y ,θ,h0)
q(z)
]
=
∫
q(β)q(pi1)
N∏
j=1
q(γj)
N∏
j=1
q(wj)[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ,θ,h0)− log q(β)]dz
−
∫
q(β)q(pi1)
N∏
j=1
q(γj)
N∏
j=1
q(wj)[log(pi1) +
N∑
j=1
(log q(γj) + log q(wj))]dz
=
∫
q(β)
[
Eq−β(log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ,θ,h0))− log q(β)
]
dβ + constant,
(16)
where q−β denotes q(pi1)
N∏
j=1
q(γj)
N∏
j=1
q(wj) and the constant does not relate to q(β). By
defining a new distribution
p˜(β) ∝ Eq−β(log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ,θ,h0)),
we can further summarize Eq. (16) as
L(q,θ) = −DKL(q(β)‖p˜(β)) + constant. (17)
From Eq. (17) we can see that the optimal q(β) is given as
q(β) = p˜(β) ∝ Eq−β [log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ,θ,h0)].
Thus,
log q(β) =Eq−β [log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ,θ,h0)] + constant
=Eq−β
[
− β
2
2σ20
−
N∑
j=1
wj
2(σ2Yj + τ
2)
(Γˆj − βγj)2
]
+ constant
=
[
− 1
2σ20
−
N∑
j=1
Eq(wjγ2j )
2(σ2Yj + τ
2)
]
β2 +
(
N∑
j=1
Eq(wjγj)Γˆj
σ2Yj + τ
2
)
β + constant,
Because log q(β) is a quadratic form, we know q(β) is the density function of an Gaussian
distribution q(β) = N (µβ, σ2β):
σ2β =
[
1
σ20
+
N∑
j=1
E(wjγ2j )
σ2Yj + τ
2
]−1
, µβ =
[
N∑
j=1
E(wjγj)Γˆj
σ2Yj + τ
2
]
σ2β.
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Similarly, the optimal solution of q(γj) is given by
log q(γj) =Eq−γj [log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ,θ,h0)] + constant
=Eq−γj
[
− 1
2σ2Xj
(γˆj − γj)2 − wj
2(σ2Yj + τ
2)
(Γˆj − βγj)2 − 1
2σ2
γ2j
]
+ constant
=− γ
2
j − 2γˆjγj + γˆ2j
2σ2Xj
− E(wjβ
2)γ2j − 2ΓˆjE(wjβ)γj
2(σ2Yj + τ
2)
− γ
2
j
2σ2
+ constant
=
[
− 1
2σ2Xj
− Eq(wjβ
2)
2(σ2Yj + τ
2)
− 1
2σ2
]
γ2j +
[
γˆj
σ2Xj
+
Eq(wjβ)Γˆj
σ2Yj + τ
2
]
γj + constant.
The quadratic form of log q(γj) indicates that q(γj) is the density of a Gaussian distribution,
i.e., q(γj) = N (µγj , σ2γj) with
σ2γj =
[
1
σ2Xj
+
E(wjβ2)
σ2Yj + τ
2
+
1
σ2
]−1
, µ2γj =
[
γˆj
σ2Xj
+
E(wjβ)Γˆj
σ2Yj + τ
2
]
σ2γj .
For latent variable pi1, accordingly, we have
q(pi1) =Eq−pi1 [log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ,θ,h0)] + constant
=Eq−pi1
{
N∑
j=1
[wj log pi1 + (1− wj) log(1− pi1)] + (a0 − 1) log pi1
}
+ constant
=
[
a0 − 1 +
N∑
j=1
Eq(wj)
]
log(pi1) +
[
N −
N∑
j=1
Eq(wj)
]
log(1− pi1) + constant.
The form of log q(pi1) suggests that q(pi1) is the density of a Beta distribution, i.e., Beta(pi1|a, b):
a = a0 +
N∑
j=1
Eq(wj), b = N + 1−
N∑
j=1
Eq(wj).
Eventually, for latent variable wj, according to coordinate ascent MFVB,
q(wj) =Eq−wj [log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ,θ,h0)] + constant
=Eq−wj
{
wj
[
−1
2
log(2pi)− 1
2
log(σ2Yj + τ
2)− 1
2(σ2Yj + τ
2)
(Γˆj − βγj)2
]}
+ Eq−wj [wj log pi1 + (1− wj) log(1− pi1)] + constant
=wj
[
−1
2
log(2pi)− 1
2
log(σ2Yj + τ
2)− Eq(Γˆj − βγj)
2
2(σ2Yj + τ
2)
]
+ wjEq[log pi1] + (1− wj)E[log(1− pi1)] + constant.
25
Notice that wj is binary and the constant has no connection with wj, here we derive
q(wj = 0)
q(wj = 1)
=
exp{E[log(1− pi1)]}
exp
{
−1
2
log(2pi)− 1
2
log(σ2Yj + τ
2)− Eq(Γˆj−βγj)2
2(σ2Yj
+τ2)
+ Eq[log pi1]
} .
Thus, q(wj) is the density of the following Bernoulli distribution: q(wj) = Bernoulli(piwj)
with
piwj = q(wj = 1) = Eq(wj) =
q(wj = 1)
q(wj = 0) + q(wj = 1)
.
Considering the form of the optimal variational distribution, the expectations of latent
variables are written as
Eq(β) = µβ, Eq(β2) = µ2β + σ2β,
Eq(γj) = µγj , Eq(γ2j ) = µ2γj + σ
2
γj
,
Eq[log(pi1)] = ψ(a)− ψ(a+ b), Eq[log(1− pi1)] = ψ(b)− ψ(a+ b),
Eq(wj) = piwj ,
where ψ(·) represents the digamma function. Noticing the independence bewteen latent
variables under the variational posterior distribution, finally we derive the updating equa-
tions for the variational E-step:
σ2β =
[
1
σ20
+
N∑
j=1
piwj(µ
2
γj
+ σ2γj)
σ2Yj + τ
2
]−1
, µβ =
(
N∑
j=1
piwjµγj Γˆj
σ2Yj + τ
2
)
σ2β,
σ2γj =
[
1
σ2Xj
+
piwj(µ
2
β + σ
2
β)
σ2Yj + τ
2
+
1
σ2
]−1
, µγj =
(
γˆj
σ2Xj
+
piwjµβΓˆj
σ2Yj + τ
2
)
σ2γj ,
a = α +
N∑
j=1
piwj , b = N + 1−
N∑
j=1
piwj ,
piwj =
qj1
qj0 + qj1
,
where
qj0 = exp[ψ(b)− ψ(a+ b)],
qj1 = exp
[
−1
2
log(2pi)− 1
2
log(σ2Yj + τ
2)− (µ
2
β + σ
2
β)(µ
2
γj
+ σ2γj)− 2µβµγj Γˆj + Γˆ2j
2(σ2Yj + τ
2)
+ ψ(a)− ψ(a+ b)
]
.
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A.2 M-step
We first evaluate the ELBO L = L(q,θ).
L =Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ,θ,h0)]− Eq[log q(z)]
=Eq[log Pr(γˆ|σ2X ,γ)] + Eq[log Pr(Γˆ|σ2Y , β,γ,w, τ 2)]
+ Eq[log Pr(β|σ20)] + Eq[log Pr(γ|σ2)] + Eq[log Pr(w|pi1)] + Eq[log Pr(pi1|a0)]
− Eq[log q(β)]− Eq[log q(γ)]− Eq[log q(w)]− Eq[log q(pi1)],
where
Eq[log Pr(γˆ|σ2X ,γ)]
=Eq
[
N∑
j=1
logN (γˆj|γj, σ2Xj)
]
=Eq
{
N∑
j=1
[−1
2
log(σ2Xj)−
1
2σ2Xj
(γˆj − γj)2]
}
+ constant
=
N∑
j=1
{
−1
2
log(σ2Xj)−
1
2σ2Xj
[(γˆj − µγj)2 + σ2γj ]
}
+ constant,
Eq[log Pr(Γˆ|σ2Y , β,γ,w, τ 2)]
=Eq
[
log
N∏
j=1
N (Γˆj|βγj, σ2Yj + τ 2)wj
]
=Eq
{
N∑
j=1
wj
[
−1
2
log(2pi)− 1
2
log(σ2Yj + τ
2)− (Γˆj − βγj)
2
2(σ2Yj + τ
2)
]}
+ constant
=
N∑
j=1
piwj
[
−1
2
log(2pi)− 1
2
log(σ2Yj + τ
2)
]
+
N∑
j=1
piwj
[
−(µ
2
β + σ
2
β)(µ
2
γj
+ σ2γj)− 2µβµγj Γˆj + Γˆ2j
2(σ2Yj + τ
2)
]
+ constant,
Eq[log Pr(β|σ20)]
=Eq
[
logN (β|0, σ20)
]
=Eq
[
−1
2
log(σ20)−
1
2σ20
β2
]
+ constant
=− 1
2σ20
(µ2β + σ
2
β) + constant,
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Eq[log Pr(γ|σ2)]
=Eq
[
N∑
j=1
logN (γj|0, σ2)
]
=Eq
{
N∑
j=1
[
−1
2
log(σ2)− 1
2σ2
γ2j
]}
+ constant
=− N
2
log(σ2)− 1
2σ2
N∑
j=1
(µ2γj + σ
2
γj
) + constant,
Eq[log Pr(w|pi1)] =Eq
[
N∑
j=1
log Bernoulli(wj|pi1)
]
=Eq
{
N∑
j=1
[wj log(pi1) + (1− wj) log(1− pi1)]
}
=
N∑
j=1
{piwj [ψ(a)− ψ(a+ b)] + (1− piwj)[ψ(b)− ψ(a+ b)]},
Eq[log Pr(pi1|a0)] =Eq[log Beta(pi1|a0, 1)]
=Eq[(a0 − 1) log(pi1)] + constant
=(a0 − 1)[ψ(a)− ψ(a+ b)] + constant,
Eq[log q(β)] =Eq
[
logN (β|µβ, σ2β)
]
=Eq
[
−1
2
log(σ2β)−
1
2σ2β
(β − µβ)2
]
+ constant
=− 1
2
log(σ2β) + constant,
Eq[log q(γ)] =Eq
[
N∑
j=1
logN (γj|µγj , σ2γj)
]
=Eq
{
N∑
j=1
[−1
2
log(σ2γj)−
1
2σ2γj
(γj − µγj)2]
}
+ constant
=− 1
2
N∑
j=1
log(σ2γj) + constant,
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Eq[log q(w)] =Eq
[
N∑
j=1
log Bernoulli(wj|piwj)
]
=Eq
{
N∑
j=1
[wj log(piwj) + (1− wj) log(1− piwj)]
}
=
N∑
j=1
[
piwj log(piwj) + (1− piwj) log(1− piwj)
]
,
Eq[log q(pi1)] =Eq[log Beta(pi1|a, b)]
=Eq{(a− 1) log(pi1) + (b− 1) log(1− pi1)− log[B(a, b)]}
=(a− 1)[ψ(a)− ψ(a+ b)] + (b− 1)[ψ(b)− ψ(a+ b)]− log[B(a, b)].
Now we derive the updating equations for parameters σ2 and τ 2.
For parameter σ2, the ELBO L terms with σ2 are given as
L[σ2] = −N
2
log(σ2)−
N∑
j=1
(
µ2γj + σ
2
γj
2σ2
)
.
Then taking derivative of ELBO L w.r.t. σ2
∂L
∂σ2
= − N
2σ2
+
1
2(σ2)2
N∑
j=1
(µ2γj + σ
2
γj
).
and setting it to zero gives the updating equation for σ2 as
σ2 =
N∑
j=1
(µ2γj + σ
2
γj
)
N
.
Similarly, for parameter τ 2, we calculate the ELBO L terms with τ 2 as
L[τ2] =
N∑
j=1
{
piwj
[
−1
2
log(σ2Yj + τ
2)− (µ
2
β + σ
2
β)(µ
2
γj
+ σ2γj)− 2µβµγj Γˆj + Γˆ2j
2(σ2Yj + τ
2)
]}
.
However, directly taking derivative w.r.t. τ 2 and setting it to zero will not give a closed-form
updating equation for τ 2. Now we propose some tricks. Consider the function f(x, y) =
x2
y
which is jointly convex in (x, y) for y > 0 (This is known as ‘Quadratic over linear’). Now
we consider function f(σ2Yj + (τ
(t))2, σ2Yj + τ
2) = [σ2Yj + (τ
(t))2](σ2Yj + τ
2)−1[σ2Yj + (τ
(t))2], and
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we are going to make use of the convexity of f(x, y): f(λx1 + (1− λ)x2, λy1 + (1− λ)y2) ≤
λf(x1, y1) + (1− λ)f(x2, y2). Denote
λ =
σ2Yj
σ2Yj + (τ
(old))2
, 1− λ = (τ
(old))2
σ2Yj + (τ
(old))2
,
x1 =
σ2Yj + (τ
(old))2
σ2Yj
σ2Yj , x2 =
σ2Yj + (τ
(old))2
(τ (old))2
(τ (old))2,
y1 =
σ2Yj + (τ
(old))2
σ2Yj
σ2Yj , y2 =
σ2Yj + (τ
(old))2
(τ (old))2
τ 2.
Then we have
[σ2Yj + (τ
(old))2](σ2Yj + τ
2)−1[σ2Yj + (τ
(old))2]
=[λx1 + (1− λ)x2][λy1 + (1− λ)y2]−1[λx1 + (1− λ)x2]
=f(λx1 + (1− λ)x2, λy1 + (1− λ)y2)
≤λf(x1, y1) + (1− λ)f(x2, y2)
=λx1y
−1
1 x1 + (1− λ)x2y−12 x2
It is easy to check
λx1y
−1
1 x1 =σ
2
Yj
,
(1− λ)x2y−12 x2 =
(τ (old))4
τ 2
.
In summary, we derive the following inequality
(σ2Yj + τ
2)−1 ≤ [σ2Yj + (τ (old))2]−2
[
σ2Yj +
(τ (old))4
τ 2
]
.
For the log term in L[τ2], we also have a bound (first-order approximation to a concave
function)
− log(σ2Yj + τ 2) ≥ − log[σ2Yj + (τ (old))2]− [σ2Yj + (τ (old))2]−1[τ 2 − (τ (old))2].
Using such two bounds, the ELBO L terms containing τ 2 are bounded as
L[τ2] ≥
N∑
j=1
−piwj [τ 2 − (τ (old))2]2[σ2Yj + (τ (old))2] − piwj2 [(µ2β + σ2β)(µ2γj + σ2γj)− 2µβµγj Γˆj + Γˆ2j ]
σ2Yj +
[τ (old)]4
τ2
[σ2Yj + (τ
(old))2]2
+ constant
Taking derivative of such bound of L[τ2] w.r.t. τ 2 and setting it to zero
N∑
j=1
{
− piwj
2[σ2Yj + (τ
(old))2]
+
piwj [(µ
2
β + σ
2
β)(µ
2
γj
+ σ2γj)− 2µβµγj Γˆj + Γˆ2j ](τ (old))4
2[σ2Yj + (τ
(old))2]2τ 4
}
= 0,
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gives the following updating equation for τ 2:
τ 2 ←
√√√√√√√√
N∑
j=1
piwj [(µ
2
β + σ
2
β)(µ
2
γj
+ σ2γj)− 2µβµγj Γˆj + Γˆ2j ](τ (old))4
[σ2Yj + (τ
(old))2]2
N∑
j=1
piwj
σ2Yj
+(τ (old))2
.
where (τ (old))2 is the estimate of τ 2 at previous iteration.
B Inference
With the mean field assumption, VEM algorithm can provide accurate posterior mean
of β (Blei et al., 2017). However, MFVB often underestimates the posterior variance of
latent variables (Blei et al., 2017). As inspired by the linear response methods (Giordano
et al., 2015, 2018), in this section we propose an exact closed-from formula to correct the
underestimated variance, yielding an accurate inference for β.
B.1 An example showing the properties of MFVB
First we give a simple example to vividly show the properties of MFVB. Suppose the true
posterior distribution is a multivariate normal distribution
p(z) = N (µ0,Σ0),
where z ∈ RM×1, µ0 ∈ RM×1, Σ0 ∈ RM×M . And we use the variational distribution q(z)
to approximate it. According to MFVB, we assume that q(z) can be factorized as
q(z) =
M∏
j=1
q(zj).
Note that in the framework of VEM and MFVB, the optimal approximation q∗(z) of p(z)
is obtained by maximizing ELBO w.r.t. q, which is equivalent to minimizing the Kullback-
Leibler (KL) divergence KL(q(z)‖p(z)) w.r.t. q. We obtain
KL(q(z)‖p(z)) = Eq(z)
[
log
q(z)
p(z)
]
=
∫ M∏
j=1
q(zj)
[
− log p(z) + log
M∏
j=1
q(zj)
]
dz. (18)
31
We now seek the minimum of KL(q(z)‖p(z)) by making optimization of KL(q(z)‖p(z))
w.r.t. q(zj), j = 1, 2, ...,M , in turn. Let z−j := {zi}i 6=j and q−j(z−j) :=
∏
i 6=j
q(zi), then we
re-arrange Eq. (18) as
KL(q(z)‖p(z)) =
∫
q(zj)
∫
q−j(z−j)[− log p(z) + log q−j(z−j) + log q(zj)]dz−jdzj
=
∫
q(zj)
∫
q−j(z−j)[− log p(z) + log q(zj)]dz−jdzj +
∫
q−j(z−j) log q−j(z−j)dz−j
=
∫
q(zj)
[
−
∫
q−j(z−j) log p(z)dz−j + log q(zj)
]
dzj +
∫
q−j(z−j) log q−j(z−j)dz−j.
By defining a new distribution p˜(zj)
log p˜(zj) :=
∫
q−j(z−j) log p(z)dz−j + constant, (19)
we further derive
KL(q(z)‖p(z)) =
∫
q(zj)[− log p˜(zj) + log q(zj)]dzj + constant
=KL(q(zj)‖p˜(zj)) + constant.
Given that the Kullback-Leibler (KL) divergence is nonnegative, we know that the optimal
q(zj) is given as
q(zj) = p˜(zj). (20)
Thus, as p(z) is a multivariate normal distribution, it is reasonable to write the optimal
q(zj) as
q(zj) = N (µj, σ2j ). (21)
Finally, from Eqs. (19,20,21), we derive
µj = µ
(j)
0 , σ
2
j = 1/[Σ
−1
0 ]
(j,j),
where µ
(j)
0 denotes the j-th element of µ0 and [Σ
−1
0 ]
(j,j) denotes the element located in the
j-th row and the j-th column of Σ−10 . Therefore,
µˆ
(MFV B)
0 = µ0,
Σˆ
(MFV B)
0 = diag
(
1/[Σ−10 ]
(1,1), 1/[Σ−10 ]
(2,2), ..., 1/[Σ−10 ]
(M,M)
)
.
(22)
As can be seen from Eq. (22), MFVB gives accurate mean estimations while it provides
no information of covariances between different variables and often gives underestimated
variances.
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B.2 An example showing the intuition for linear response variational Bayes
(LRVB)
We provides intuition for linear response variational Bayes (Giordano et al., 2015) by con-
tinuing the above example. For the sake of simplicity, we assume
p(z) = N (µ0,Σ0),
z = (z1, z2),
µ0 = (µ0,1, µ0,2),
Σ0 =
a11 a12
a21 a22
 , Σ−10 =
r11 r12
r21 r22
 .
q(z) = q(z1)q(z2), q(z1) = N (µ1, σ21), q(z2) = N (µ2, σ22).
and let η be the collection of variational parameters, i.e.,
η = {µ1, σ21, µ2, σ22}.
Here we denote p0(z) as the true posterior of interest, i.e, p0(z) = p(z), and we define
a perturbation of the posterior as
pt(z) :=
p0(z) exp(t
Tz)∫
p0(z) exp(tTz)dz
. (23)
Recall that p0(z) = N (µ0,Σ0), Eq. (23) implies
log pt(z) =− 1
2
(z− µ0)TΣ−10 (z− µ0) + tTz + constant
=− 1
2
zTΣ−10 z + (µ
T
0 Σ
−1
0 + t
T )z + constant
=− 1
2
[z− (µ0 + Σ0t)]TΣ−10 [z− (µ0 + Σ0t)] + constant.
(24)
The quadratic form in Eq. (24) yields
pt(z) = N (µ0 + Σ0t,Σ0), (25)
implying
Covp(z)[z] = Σ0 =
∂Ept(z) [z]
∂tT
∣∣∣∣
t=0
. (26)
Eq. (26) shows that the sensitivity of posterior mean at t = 0 can provide information
about the true posterior variance.
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We now introduce the key idea to approximate the posterior covariance matrix in Eq.
(26) from MFVB. Let qt(z) be the mean field approximation to pt(z), i.e.,
qt(z) := q(z;η
∗
t ) = arg minqKL(q(z;η)‖pt(z)).
Since MFVB often provides accurate inference on posterior mean (Blei et al., 2017), we
assume the following conditions hold:
Condition 1: Eqt [z] ≈ Ept [z] for all t, and
Condition 2:
∂Eqt [z]
∂tT
∣∣∣∣
t=0
≈ ∂Ept [z]
∂tT
∣∣∣∣
t=0
.
(27)
Condition 1 says that MFVB can provide good approximations to posterior means of all the
perturbations. Condition 2 further requires the accuracy of the first order approximation
at t = 0. Consequently, from Eq. (26) and Condition 2 in Eq. (27), we know that the
posterior covariance matrix Σ0 can be approximated by
Σ0 ≈ ∂Eqt [z]
∂t
∣∣∣∣
t=0
=
dEqt [z]
dη
∣∣∣∣
η=η∗0
dη∗t
dt
∣∣∣∣
t=0
, (28)
where η∗0 is exactly the MFVB solution obtained in Section 2.1.
We now use properties of MFVB solution to calculate
dη∗t
dt
∣∣∣
t=0
. Importantly, note that
KL(q(z;η)‖pt(z)) can be viewed as a function of t, η, and using q(z;η) to approximate
pt(z) in the framework of MFVB is equivalent to minimizing KL(q(z;η)‖pt(z)) w.r.t. η.
The minimization yeilds
∂KL(q(z;η)‖pt(z))
∂η
∣∣∣∣
η=η∗t
= 0.
By taking derivative w.r.t. t, we then derive
d
dt
(
∂KL(q(z;η)‖pt(z))
∂η
∣∣∣∣
η=η∗t
)
= 0,
yeilding
∂2KL(q(z;η)‖pt(z))
∂η∂ηT
∣∣∣∣
η=η∗t
dη∗t
dt
+
∂2KL(q(z;η)‖pt(z))
∂t∂ηT
∣∣∣∣
η=η∗t
= 0. (29)
The strict minimization of KL(q(z;η)‖pt(z)) requires that ∂2KL(q(z;η)‖pt(z))∂η∂ηT
∣∣∣
η=η∗t
is a posi-
tive definite matrix. So we can evaluate Eq. (29) at t = 0 and solve it to find that
dη∗t
dtT
∣∣∣∣
t=0
= −
(
∂2KL(q(z;η)‖pt(z))
∂η∂ηT
∣∣∣∣
η=η∗0
)−1
∂2KL(q(z;η)‖pt(z))
∂t∂ηT
∣∣∣∣∣∣
η=η∗0 ,t=0
. (30)
34
As the KL divergence is written as
KL(q(z;η)‖pt(z)) = Eq(z;η)[log q(z;η)− log p(z)− tTz] + constant,
where the constant is not relevant to η, the term ∂
2KL(q(z;η)‖pt(z))
∂t∂ηT
∣∣∣
η=η∗,t=0
can be further
summarized as
∂2KL(q(z;η)‖pt(z))
∂t∂ηT
∣∣∣∣
η=η∗0 ,t=0
= − ∂Eq(z;η)[z]
∂ηT
∣∣∣∣
η=η∗0
. (31)
Finally, Eqs. (28,30,31) indicate an estimator of the posterior covariance matrix as
Σˆ
(LRV B)
0 :=
(
∂Eq(z;η)[z]
∂ηT
∣∣∣∣
η=η∗0
)T (
∂2KL(q(z;η)‖p(z))
∂η∂ηT
∣∣∣∣
η=η∗0
)−1(
∂Eq(z;η)[z]
∂ηT
∣∣∣∣
η=η∗0
)
.
In the above Gaussian example, KL(q(z;η)‖p(z)) is given as
KL(q(z;η)‖p(z)) =Eq(z;η)[log q(z;η)]− Eq(z;η)[log p(z)]
=− 1
2
log(σ21)−
1
2
log(σ22)
+
1
2
r11[(µ1 − µ0,1)2 + σ21] +
1
2
r22[(µ2 − µ0,2)2 + σ22] + r12(µ1 − µ0,1)(µ2 − µ0,2)
+ constant.
Thus, in this case,
∂2KL(q(z;η)‖p(z))
∂η∂ηT
∣∣∣∣
η=η∗0
=

r11 0 r12 0
0 1
2σ41
0 0
r21 0 r22 0
0 0 0 1
2σ42
.

Note that we already have
σ21 = 1/r11, σ
2
2 = 1/r22,
a11 a12
a21 a22
 =
r11 r12
r21 r22
−1 = 1
r11r22 − r12r21
 r22 −r12
−r21 r11
 .
With
∂Eq(z;η)[z]
∂ηT
∣∣∣∣
η=η∗0
=
1 0 0 0
0 0 1 0
T ,
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We finally calculate Σˆ
(LRV B)
0 as
Σˆ
(LRV B)
0 =
1 0 0 0
0 0 1 0


r11 0 r12 0
0 1
2σ41
0 0
r21 0 r22 0
0 0 0 1
2σ42
.

−1 1 0 0 0
0 0 1 0
T =
a11 a12
a21 a22
 = Σ0.
This Gaussian example not only gives the intuition of LRVB, but also helps to show that
LRVB can indeed correct the covariance estimation provided by MFVB.
B.3 Inference of posterior variance of one specific latent variable
Note that, for BWMR model, in the inference part we only seek to derive the posterior
variance of latent variable β, i.e., we only care about the inference of one specific latent
variable among all latent variables. Before implementing inference for BWMR, we continue
the Gaussian example to get more intuition.
Let t = (t1, 0) in pt(z) = N (µ0 + Σ0t,Σ0) (Eq. (25)), we then have
pt1(z) = N ((µ0,1 + a11t1, µ0,2 + a12t1),Σ0). (32)
It is not hard to find out that Eq. (32) corresponds to the perturbation
pt1(z) =
p(z) exp(t1z1)∫
p(z) exp(t1z1)dz
.
Eq. (32) indicates an approximation to Var(z1):
Var(z1) = a11 =
dEpt1 [z1]
dt1
∣∣∣∣
t1=0
≈ dEqt1 [z1]
dt1
∣∣∣∣
t1=0
= V̂ar(z1),
where qt1(z) is the optimal solution of variational distribution used to approximate pt1(z)
in the framework of MFVB. Then
V̂ar(z1) =
∂Eqt1 [z1]
∂η
∣∣∣∣
η=η∗0
dη∗t1
dt1
∣∣∣∣
t1=0
, (33)
where η∗t1 is the optimal solution of η when approximating pt1(z), and η
∗
0 = η
∗
t1
|t1=0 still
represents the optimal solution of η when approximating true posterior p0(z) = p(z).
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To conveniently derive
dη∗t1
dt1
∣∣∣∣
t1=0
, similar as Eqs. (29,30), we now have
∂2KL(q(z;η)‖pt1(z))
∂η∂ηT
∣∣∣∣
η=η∗t1
dη∗t1
dt1
+
∂2KL(q(z;η)‖pt1(z))
∂t1∂ηT
∣∣∣∣
η=η∗t1
= 0,
indicating
dη∗t1
dt1
∣∣∣∣
t1=0
= −
(
∂2KL(q(z;η)‖pt1(z))
∂η∂ηT
∣∣∣∣
η=η∗0 ,t1=0
)−1
∂2KL(q(z;η)‖pt1(z))
∂t1∂ηT
∣∣∣∣∣∣
η=η∗0 , t1=0
.
(34)
Then similar as the derivation of Eq. (31), given that now the KL divergenceKL(q(z;η)‖pt1(z))
is written as
KL(q(z;η)‖pt1(z)) = Eq(z;η)[log q(z;η)− log p(z)− t1z1] + constant,
where the constant is not relevant to η, we summary the term
∂2KL(q(z;η)‖pt1 (z))
∂t1∂ηT
∣∣∣
η=η∗0 ,t1=0
as
∂2KL(q(z;η)‖pt1(z))
∂t1∂ηT
∣∣∣∣
η=η∗0 ,t1=0
= − ∂Eq(z;η)[z1]
∂ηT
∣∣∣∣
η=η∗0
. (35)
From Eq. (33,34,35), we finally derive
V̂ar(z1) =
(
∂Eq(z;η)[z1]
∂ηT
∣∣∣∣
η=η∗0
)T (
∂2DKL(q(z;η)‖p(z))
∂η∂ηT
∣∣∣∣
η=η∗0
)−1(
∂Eq(z;η)[z1]
∂ηT
∣∣∣∣
η=η∗0
)
=[1, 0, 0, 0]

r11 0 r12 0
0 1
2σ41
0 0
r21 0 r22 0
0 0 0 1
2σ42
.

−1
[1, 0, 0, 0]T
=a11
=Var(z1).
B.4 Detailed derivations for inference
For BWMR, z denotes the latent variables and D denotes the input data. For notation
convenience, we denote p0(z) as the true posterior of interest, i.e., p0(z) = Pr(z|D). As we
want to derive the accurate posterior variance of latent β, inspired by the inference of z1
37
in the Gaussian example, here we define a perturbation of the posterior p0(z) = Pr(z|D)
in BWMR as
pt(z) :=
p0(z) exp(tβ)∫
p0(z) exp(tβ)dz
.
Let
C(t) := log
∫
p0(z) exp(tβ)dz. (36)
Then the perturbation pt(z) is written as
pt(z) = p0(z) exp(tβ − C(t)),
where C(t) normalizes pt(z).
• use the cumulant generating properties
We introduce a new variable u and seek to derive the cumulant generating function Kpt(u)
for pt(z). From the definition of the cumulant generating function as well as Eq. (36), we
have
Kpt(u) = logEpt [exp(uβ)]
= log
∫
exp(uβ)p0(z) exp(tβ − C(t))dz
= log
∫
p0(z) exp((u+ t)β)dz− C(t)
=C(u+ t)− C(t).
The properties of the cumulant generating function implies
Ept [β] =
∂Kpt(u)
∂u
∣∣∣∣
u=0
=
dC(t)
dt
,
Varpt [β] =
∂2Kpt(u)
∂u2
∣∣∣∣
u=0
=
d2C(t)
dt2
.
Therefore we get
VarPr(z|D)[β] = Varp0 [β] = Varpt [β]|t=0 =
dEpt [β]
dt
∣∣∣∣
t=0
. (37)
• use the properties of MFVB solution
Eq. (37) provides insight of using the accurate mean estimation from MFVB to correct
the posterior variance inference. However, in practice we seek to only implement VEM
38
and MFVB once without any perturbations of the posterior. The usage of MFVB solution
properties helps to address this problem.
The variational distributions from MFVB is
q(z) = q(β)q(pi1)
N∏
j=1
q(γj)
N∏
j=1
q(wj),
with
q(β) = N (µβ, σ2β), q(γj) = N (µγj , σ2γj),
q(wj) = Bernoulli(piwj), q(pi1) = Beta(a, b).
We now use the variational distribution
q(z;η) = q(z),
with the collection of variational parameters
η = {µβ, σ2β, µγ1 , σ2γ1 , piw1 , ..., µγj , σ2γj , piwj , ..., µγN , σ2γN , piwN , a, b}
to approximate the perturbation pt(z) of the posterior p0(z) = Pr(z|D). Let qt(z) = q(z;η∗t )
denotes the optimal solution of variational distribution in MFVB when inferring pt(z|D),
with η∗t denoting the corresponding optimal solution of η. Note that Pr(z|D) = pt(z)|t=0.
Let q0(z) = qt(z)|t=0 and η∗0 = η∗t |t=0 refer to the optimal solution in the VEM algorithm
for BWMR. Since MFVB often provides accurate inference on posterior mean, similar as
in the Gaussian example, here we assume the following conditions hold:
Condition 1: Eqt [β] ≈ Ept [β] for all t, and
Condition 2:
dEqt [β]
dt
∣∣∣∣
t=0
≈ dEpt [β]
dt
∣∣∣∣
t=0
.
Then we now have
VarPr(z|D)[β] =
dEpt [β]
dt
∣∣∣∣
t=0
≈ dEqt [β]
dt
∣∣∣∣
t=0
=: V̂arPr(z|D)[β],
V̂arPr(z|D)[β] =
∂Eq(z;η)[β]
∂η
∣∣∣∣
η=η∗0
dη∗t
dt
∣∣∣∣
t=0
.
(38)
39
Similar as Eq. (34) and Eq. (35), we can derive
dη∗t
dt
∣∣∣∣
t=0
= −
(
∂2KL(q(z;η)‖pt(z|D))
∂η∂ηT
∣∣∣∣
η=η∗0 , t=0
)−1
∂2KL(q(z;η)‖pt(z|D))
∂t∂ηT
∣∣∣∣∣∣
η=η∗0 ,t=0
,
∂2KL(q(z;η)‖pt(z|D))
∂t∂ηT
∣∣∣∣
η=η∗0 ,t=0
= − ∂Eq(z;η)[β]
∂η
∣∣∣∣
η=η∗0
.
(39)
Recall that the ELBO L in VEM algorithm can be written as
L = −KL(q(z;η)‖Pr(z|D)) + constant,
where the constant is not relevant to η, indicating
∂2KL(q(z;η)‖Pr(z|D))
∂η∂ηT
= − ∂
2L
∂η∂ηT
. (40)
Combining Eqs. (38, 39, 40), we finally derive the estimator of posterior variance of β
as
V̂arPr(z|D)(β) = −gTH−1g, (41)
where
g =
∂Eq(z;η)[β]
∂ηT
∣∣∣∣
η=η∗0
, H =
∂2L
∂η∂ηT
∣∣∣∣
η=η∗0
. (42)
• calculate the matrix H
The first derivatives of ELBO L is given as
∂L
∂µβ
= −
(
N∑
j=1
piwj
µβ(µ
2
γj
+ σ2γj)− µγj Γˆj
σ2Yj + τ
2
)
− µβ
σ20
,
∂L
∂σ2β
= −
(
N∑
j=1
piwj(µ
2
γj
+ σ2γj)
2(σ2Yj + τ
2)
)
− 1
2σ20
+
1
2σ2β
,
∂L
∂µγj
= −µγj − γˆj
σ2Xj
− piwj
µγj(µ
2
β + σ
2
β)− µβΓˆj
σ2Yj + τ
2
− µγj
σ2
,
∂L
∂σ2γj
= − 1
2σ2Xj
− piwj(µ
2
β + σ
2
β)
2(σ2Yj + τ
2)
− 1
2σ2
+
1
2σ2γj
,
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∂L
∂piwj
=− log(2pi)
2
− log(σ
2
Yj
+ τ 2)
2
− (µ
2
β + σ
2
β)(µ
2
γj
+ σ2γj)− 2µβµγj Γˆj + Γˆ2j
2(σ2Yj + τ
2)
+ ψ(a)− ψ(b) + log
(
1− piwj
piwj
)
,
∂L
∂a
=ψ′(a)(a0 − a+
N∑
j=1
piwj) + ψ
′(a+ b)(a+ b− 1−N − a0),
∂L
∂b
=ψ′(b)(N + 1− b−
N∑
j=1
piwj) + ψ
′(a+ b)(a+ b− 1−N − a0).
Among the second derivatives of ELBO L, those do not have zero-values, are written
as
∂2L
∂µβ∂µβ
= −
(
N∑
j=1
piwj(µ
2
γj
+ σ2γj)
σ2Yj + τ
2
)
− 1
σ20
,
∂2L
∂µβ∂µγj
=
∂2L
∂µγj∂µβ
= −piwj(2µβµγj − Γˆj)
σ2Yj + τ
2
,
∂2L
∂µβ∂σ2γj
=
∂2L
∂σ2γj∂µβ
= − piwjµβ
σ2Yj + τ
2
,
∂2L
∂µβ∂piwj
=
∂2L
∂piwj∂µβ
= −µβ(µ
2
γj
+ σ2γj)− µγj Γˆj
σ2Yj + τ
2
,
∂2L
∂σ2β∂σ
2
β
= − 1
2(σ2β)
2
,
∂2L
∂σ2β∂µγj
=
∂2L
∂µγj∂σ
2
β
= − piwjµγj
σ2Yj + τ
2
,
∂2L
∂σ2β∂σ
2
γj
=
∂2L
∂σ2γj∂σ
2
β
= − piwj
2(σ2Yj + τ
2)
,
∂2L
∂σ2β∂piwj
=
∂2L
∂piwj∂σ
2
β
= − µ
2
γj
+ σ2γj
2(σ2Yj + τ
2)
,
∂2L
∂µγj∂µγj
= − 1
σ2Xj
− piwj(µ
2
β + σ
2
β)
σ2Yj + τ
2
− 1
σ2
,
∂2L
∂µγj∂piwj
=
∂2L
∂piwj∂µγj
= −µγj(µ
2
β + σ
2
β)− µβΓˆj
σ2Yj + τ
2
,
∂2L
∂σ2γj∂σ
2
γj
= − 1
2(σ2γj)
2
,
∂2L
∂σ2γj∂piwj
=
∂2L
∂piwj∂σ
2
γj
= − µ
2
β + σ
2
β
2(σ2Yj + τ
2)
,
∂2L
∂piwj∂piwj
= − 1
piwj
− 1
1− piwj
,
41
∂2L
∂piwj∂a
=
∂2L
∂a∂piwj
= ψ′(a),
∂2L
∂piwj∂b
=
∂2L
∂b∂piwj
= −ψ′(b),
∂2L
∂a∂a
= ψ′′(a)(a0 − a+
N∑
j=1
piwj)− ψ′(a) + ψ′′(a+ b)(a+ b− a0 − 1−N) + ψ′(a+ b),
∂2L
∂a∂b
=
∂2L
∂b∂a
= ψ′′(a+ b)(a+ b− a0 − 1−N) + ψ′(a+ b),
∂2L
∂b∂b
= ψ′′(b)(N + 1− b−
N∑
j=1
piwj)− ψ′(b) + ψ′′(a+ b)(a+ b− a0 − 1−N) + ψ′(a+ b).
• calculate the vector g
g =
∂Eq(z;η)[β]
∂η
∣∣∣∣
η=η∗0
=
∂µβ
∂η
∣∣∣∣
η=η∗0
= [1, 0, 0, ..., 0, 0]T .
• Numerical problem of the matrix H
When the variational parameter piwj is close to its boundary 0, 1, the term
∂2L
∂piwj ∂piwj
=
− 1
piwj
− 1
1−piwj
makes the matrix H numerically not invertible.
• Address the numerical problem by a reparameterized trick
Note that
∂2L
∂piwj∂piwj
= − 1
piwj
− 1
1− piwj
=
∂2Eq(z;η)[− log q(z;η)]
∂piwj∂piwj
.
The numerical problem is deal with the term
∂2Eq(z;η)[− log q(z;η)]
∂η∂ηT
∣∣∣
η=η∗0
. Next we introduce a
reparameterized trick to address the numerical problem.
The variational distribution q(z;η)
q(z;η) = q(β;η)q(pi1;η)
N∏
j=1
q(γj;η)
N∏
j=1
q(wj;η),
with
q(β;η) = N (µβ, σ2β), q(γj;η) = N (µγj , σ2γj),
q(wj;η) = Bernoulli(piwj), q(pi1;η) = Beta(a, b),
η = {µβ, σ2β, µγ1 , σ2γ1 , piw1 , ..., µγj , σ2γj , piwj , ..., µγN , σ2γN , piwN , a, b},
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is in an exponential family, i.e., the variational distribution can be written in the following
form:
q(z;η) = exp(ζTzs − A(ζ)),
where zs = T (z) are the sufficient statistics, ζ = h(η), h(·) and A(·) are known functions.
Then the entropy Eq(z;η)[− log q(z;η)] can be written as
Eq(z;η)[− log q(z;η)] = −ζTEq(z;η)[zs] + A(ζ). (43)
Moreover, using the cumulant generating properties again yeilds
Eq(z;η)[zs] =
∂A(ζ)
∂ζ
,
Covq(z;η)[zs] =
∂2A(ζ)
∂ζT∂ζ
,
indicating
Covq(z;η)[zs] =
∂Eq(z;η)[zs]
∂ζ
. (44)
For notation convenience, let
m := Eq(z;η)[zs]. (45)
Then combining Eqs. (43,44,45), we derive
∂Eq(z;η)[− log q(z;η)]
∂m
=
∂[−ζTm + A(ζ)]
∂ζT
∂ζ
∂m
+
∂[−ζTm + A(ζ)]
∂m
=
(
−m + ∂A(ζ)
∂ζ
)
∂ζ
∂m
− ζ
=− ζ,
and
∂2Eq(z;η)[− log q(z;η)]
∂m∂mT
= − ∂ζ
∂m
= −
(
∂m
∂ζ
)−1
= −(Covq(z;η)[zs])−1. (46)
Note that q(β), q(γj), q(wj), q(pi1) can be written in exponential family forms as
q(β) =
1√
2piσ2β
exp
(
− 1
2σ2β
(β − µβ)2
)
=
1√
2piσ2β
exp
(
− µβ
2σ2β
)
exp
(
µβ
σ2β
β − 1
2σ2β
β2
)
,
q(γj) =
1√
2piσ2γj
exp
(
− 1
2σ2γj
(γj − µγj)2
)
=
1√
2piσ2γj
exp
(
− µγj
2σ2γj
)
exp
(
µγj
σ2γj
γj − 1
2σ2γj
γ2j
)
,
q(wj) = pi
wj
wj
(1− piwj)1−wj = (1− piwj) exp
[
(log piwj − log(1− piwj))wj
]
,
q(pi1) =
pia−11 (1− pi1)b−1
B(a, b)
=
1
B(a, b)
exp[(a− 1) log pi1 + (b− 1) log(1− pi1)],
43
where B(·, ·) denotes the beta function. Clearly, we get the sufficient statistics of latent
variables as
T (β) = (β, β2), T (γj) = (γj, γ
2
j )
T (wj) = wj, T (pi1) = (log pi1, log(1− pi1)),
implying
zs = T (z)
= (T (β), T (γ1), T (w1), ..., T (γj), T (wj), ..., T (γN), T (wN), T (pi1))
= (β, β2, γ1, γ
2
1 , w1, ..., γj, γ
2
j , wj, ..., γN , γ
2
N , wN , log pi1, log(1− pi1)).
Then we derive m as
m =Eq[zs]
=(mβ,1,mβ,2,mγ1,1 ,mγ1,2 ,mw1 , ...,mγj,1 ,mγj,2 ,mwj , ...,mγN,1 ,mγN,1 ,mwN ,mpi1,1 ,mpi1,2),
with
mβ,1 := Eq[β] = µβ, mβ,2 := Eq[β2] = µ2β + σ2β,
mγj ,1 := Eq[γj] = µγj , mγj ,2 := Eq[γ2j ] = µ2γj + σ
2
γj
mwj := Eq[wj] = piwj ,
mpi1,1 := Eq[log pi1] = ψ(a)− ψ(a+ b), mpi1,2 := Eq[log(1− pi1)] = ψ(b)− ψ(a+ b).
Importantly, note that the variational distribution q(z) = q(z;η) can also be parameter-
ized by the vector m, here adopt this reparamterized trick and let q(z) = q(z; m) represents
the variational distribution paramterized by m. We assume that the parameters η∗0 (opti-
mal solution of η) and m∗0 (optimal solution of m) in MFVB from the VEM algorithm are
in the interior of their feasible space. Then under the same conditions (Condition 1, 2),
similar as the result in Eqs. (41, 42), i.e.,
V̂arPr(z|D)(β) = −gTH−1g,
where
g =
∂Eq(z;η)[β]
∂ηT
∣∣∣∣
η=η∗0
, H =
∂2L
∂η∂ηT
∣∣∣∣
η=η∗0
,
with the reparameterization we now have
V̂arPr(z|D)(β) = −gTm(Hmm)−1gm,
44
where
gm =
∂Eq(z;m)[β]
∂mT
∣∣∣∣
m=m∗0
, Hmm =
∂2L
∂m∂mT
∣∣∣∣
m=m∗0
.
Note that the
L = Eq(z;m)[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)] + Eq(z;m)[− log q(z; m)],
and that the results given in Eq. (46) as
∂2Eq(z;m)[− log q(z; m)]
∂m∂mT
= −(Covq(z;m)[zs])−1.
Let
H1mm :=
∂2Eq(z;m)[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
∂m∂mT
∣∣∣∣∣
m=m∗0
, V := Covq(z;m)[zs]
∣∣
m=m∗0
.
Then we can write (Hmm)
−1 as
(Hmm)
−1 = (H1mm −V−1)−1 = (VH1mm − I)−1V.
Calculating (Hmm)
−1 in this way can prevent the numerical unstability in practice, because
the term corresponding to − 1
wj
− 1
1−wj = − 1wj(1−wj) becomes wj(1− wj) in matrix V.
• calculate matrix V
Recall that V = Covq(z;m)[zs]
∣∣
m=m∗0
. As MFVB provides no information of covariances be-
tween different latent variables , we only need to calculate the covriance matrices Covq(z)[T (β)],
Covq(z)[T (γj)], Covq(z)[T (wj)], Covq(z)[T (pi1)]. Intuitively, we give a illustrative diagram for
matrix V in the following Figure.
As q(β) and q(γj) are normal distributions, the covariance matrices Covq(z)[T (β)],Covq(z)[T (γj)]
are given as
Covq(z)[T (β)] =
 Varq(β) Covq(β, β2)
Covq(β
2, β) Varq(β
2)
 ,
Covq(z)[T (γj)] =
 Varq(γj) Covq(γj, γ2j )
Covq(γ
2
j , γj) Varq(γ
2
j )
 .
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Figure 5: Sparsity pattern for the (3N + 4)× (3N + 4) matrix V. For simplicity, here we
choose N = 5 as an example.
Recall that q(β) = N (µβ, σ2β), and that if ξ ∼ N (ξ|0, 1) then
E(ξk) =
 (k − 1)!!, k = 2n, n ∈ N+,0, k = 2n− 1, n ∈ N+.
To use this property, we rewrite β as β = σβ
(
β−µβ
σβ
+
µβ
σβ
)
= σβ
(
ξ +
µβ
σβ
)
. Therefore, we
have
Eq(β2) = µ2β + σ2β,
Eq(β3) = E
[
σ3β
(
ξ +
µβ
σβ
)3]
= σ3βE
[
ξ3 + 3
µβ
σβ
ξ2 + 3
(
µβ
σβ
)2
ξ +
(
µβ
σβ
)3]
= 3µβσ
2
β + µ
3
β,
Eq(β4) = E
[
σ4β
(
ξ +
µβ
σβ
)4]
= σ4βE
[
ξ4 + 4
µβ
σβ
ξ3 + 6
(
µβ
σβ
)2
ξ2 + 4
(
µβ
σβ
)3
ξ +
(
µβ
σβ
)4]
= 3σ4β + 6µ
2
βσ
2
β + µ
4
β,
Then, we derive
Varq(β
2) = E(β4)− E2(β2) = 3σ4β + 6µ2βσ2β + µ4β − (σ2β + µ2β)2 = 2σ4β + 4µ2βσ2β,
Cov(β2, β) = E(β3)− E(β2)E(β) = 3µβσ2β + µ3β − (σ2β + µ2β)µβ = 2µβσ2β,
yielding
Covq(z)[T (β)] =
 σ2β 2µβσ2β
2µβσ
2
β 2σ
4
β + 4µ
2
βσ
2
β
 .
Similarly, we have
Covq(z)[T (γj)] =
 σ2γj 2µγjσ2γj
2µγjσ
2
γj
2σ4γj + 4µ
2
γj
σ2γj
 .
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Given that q(wj) = Bernoulli(piwj), the variance of wj is given as
Varq(z)[T (wj)] = Eq(w2j )− E2q(wj) = piwj − pi2wj .
Recall that q(pi1) = Beta(a, b) and T (pi1) = (log pi1, log(1− pi1)), then we know
Covq(z)[T (pi1)] =
 Varq(log pi1) Covq(log pi1, log(1− pi1))
Covq(log(1− pi1), log pi1) Varq(log(1− pi1))
 . (47)
It is not hard to derive
Varq(log pi1) = ψ1(a)− ψ1(a+ b),
where ψ1(·) represents the trigamma function. Note that (1 − pi1) ∼ Beta(b, a), then we
know
Varq(log(1− pi1)) = ψ1(b)− ψ1(a+ b).
To calculate Covq(log(1− pi1), log pi1), we need to find Eq[log pi1 log(1− pi1)] firstly:
Eq[log pi1 log(1− pi1)] =
∫ 1
0
log x log(1− x)x
a−1(1− x)b−1
B(a, b)
dx.
Note that,
∂2[xa−1(1− x)b−1]
∂a∂b
=
∂2[xa−1(1− x)b−1]
∂b∂a
= log x log(1− x)xa−1(1− x)b−1.
Therefore,
Eq[log pi1 log(1− pi1)] = 1
B(a, b)
∫ 1
0
∂2[xa−1(1− x)b−1]
∂a∂b
dx
=
1
B(a, b)
∂2
∂a∂b
∫ 1
0
xa−1(1− x)b−1dx
=
1
B(a, b)
∂2B(a, b)
∂a∂b
.
With detailed derivations as
∂B(a, b)
∂a
=
∂
∂a
[
Γ(a)Γ(b)
Γ(a+ b)
]
=Γ(b)
Γ′(a)Γ(a+ b)− Γ(a)Γ′(a+ b)
Γ2(a+ b)
=
Γ(a)Γ(b)
Γ(a+ b)
[
Γ′(a)
Γ(a)
− Γ
′(a+ b)
Γ(a+ b)
]
=B(a, b)[ψ(a)− ψ(a+ b)]
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and
∂2B(a, b)
∂b∂a
=
∂B(a, b)
∂b
[ψ(a)− ψ(a+ b)] + B(a, b) ∂
∂b
[ψ(a)− ψ(a+ b)]
=B(a, b)[ψ(b)− ψ(a+ b)][ψ(a)− ψ(a+ b)]− B(a, b)ψ1(a+ b)
=B(a, b){[ψ(b)− ψ(a+ b)][ψ(a)− ψ(a+ b)]− ψ1(a+ b)},
we finally derive
Eq[log pi1 log(1− pi1)] = [ψ(a)− ψ(a+ b)][ψ(b)− ψ(a+ b)]− ψ1(a+ b). (48)
Further considering that Eq[log pi1] = ψ(a) − ψ(a + b), Eq[log(1 − pi1)] = ψ(b) − ψ(a + b)
and Eq. (48), we have
Covq(log pi1, log(1− pi1)) =Eq[log p(pi1) log p(1− pi1)]− Eq[log p(pi1)]Eq[log p(1− pi1)]
=[ψ(a)− ψ(a+ b)][ψ(b)− ψ(a+ b)]− ψ1(a+ b)
− [ψ(a)− ψ(a+ b)][ψ(b)− ψ(a+ b)]
=− ψ1(a+ b),
i.e.,
Covq(z)(log pi1, log(1− pi1)) = Covq(z)(log(1− pi1), log pi1) = −ψ1(a+ b).
Thus, we derive
Covq(z)[T (pi1)] =
ψ1(a)− ψ1(a+ b) −ψ1(a+ b)
−ψ1(a+ b) ψ1(b)− ψ1(a+ b)
 .
• calculate matrix H1mm
Recall that H1mm =
∂2Eq [log Pr(γˆ,Γˆ,z|σ2X ,σ2Y ;θ;h0)]
∂mT ∂m
∣∣∣
m=m∗0
. To calculate matrix H1mm, we summa-
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rize the terms with m in Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)] as:
Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
=
N∑
j=1
(
−mγj,2 − 2γˆjmγj,1
2σ2Xj
)
+
N∑
j=1
mwj
[
−1
2
log(2pi)− 1
2
log(σ2Yj + τ
2)− mβ,2mγj,2 − 2mβ,1Γˆjmγj,1 + Γˆ
2
j
2(σ2Yj + τ
2)
]
− mβ,2
2σ20
+
N∑
j=1
(
−mγj,2
2σ2
)
+
N∑
j=1
[
mwjmpi1,1 + (1−mwj)mpi1,2
]
+ (a0 − 1)mpi1,1
+ constant.
Therefore we can calculate
∂2Eq [log Pr(γˆ,Γˆ,z|σ2X ,σ2Y ;θ;h0)]
∂mT ∂m
as follows. The first derivatives are
given as
∂Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
∂mβ,1
=
N∑
j=1
mwj Γˆjmγj ,1
σ2Yj + τ
2
,
∂Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
∂mβ,2
=−
N∑
j=1
[
mwjmγj ,2
2(σ2Yj + τ
2)
]
− 1
2σ20
,
∂Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
∂mγj ,1
=
γˆj
σ2Xj
+
mwjmβ,1Γˆj
σ2Yj + τ
2
,
∂Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
∂mγj ,2
=− 1
2σ2Xj
− mwjmβ,2
2(σ2Yj + τ
2)
− 1
2σ2
,
∂Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
∂mwj
=− 1
2
log(2pi)− 1
2
log(σ2Yj + τ
2)
−mβ,2mγj,2 − 2mβ,1Γˆjmγj,1 + Γˆ
2
j
2(σ2Yj + τ
2)
+mpi,1 −mpi,2,
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∂Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
∂mpi,1
=(a0 − 1) +
N∑
j=1
mwj ,
∂Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
∂mpi,2
=N −
N∑
j=1
mwj .
Among the second derivatives, those which do not have zero values are:
∂2Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
∂mβ,1∂mγj ,1
=
∂2Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
∂mγj ,1∂mβ,1
=
mwj Γˆj
σ2Yj + τ
2
,
∂2Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
∂mβ,1∂mwj
=
∂2Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
∂mwj∂mβ,1
=
mγj ,1Γˆj
σ2Yj + τ
2
,
∂2Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
∂mβ,2∂mγj ,2
=
∂2Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
∂mγj ,2∂mβ,2
= − mwj
2(σ2Yj + τ
2)
,
∂2Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
∂mβ,2∂mwj
=
∂2Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
∂mwj∂mβ,2
= − mγj ,2
2(σ2Yj + τ
2)
,
∂2Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
∂mγj ,1∂mwj
=
∂2Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
∂mwj∂mγj ,1
=
mβ,1Γˆj
σ2Yj + τ
2
,
∂2Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
∂mγj ,2∂mwj
=
∂2Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
∂mwj∂mγj ,2
= − mβ,2
2(σ2Yj + τ
2)
,
∂2Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
∂mpi,1∂mwj
=
∂2Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
∂mwj∂mpi,1
= 1,
∂2Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
∂mpi,2∂mwj
=
∂2Eq[log Pr(γˆ, Γˆ, z|σ2X ,σ2Y ;θ;h0)]
∂mwj∂mpi,2
= −1.
We finally derive the matrix H1mm. Intuitively, we give a illustrative diagram for matrix
H1mm in the following figure:
• calculate the vector gm
gm =
∂Eq(z;m)[β]
∂m
∣∣∣∣
η=η∗0
=
∂mβ,1
∂m
∣∣∣∣
m=m∗0
= [1, 0, 0, ..., 0, 0]T .
• calculate the standard error of β
Finally, the standard error of β is provided as the element in the first row and the first
column of the matrix Hmm = (VH
1
mm − I)−1V.
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Figure 6: Sparsity pattern for the (3N + 4)× (3N + 4) matrix H1mm. For simplicity, here
we choose N = 5 as an example.
C Comparison of different MR Methods
Methods like Egger and GSMR are closely related to standard Inverse Variance Weighted
(IVW) meta analysis approach. The development of these MR methods put more efforts
to address the issue of horizontal pleiotropy. To connect these methods, we first introduce
the IVW method here.
Assuming that the involved genetic variants satisfy the conditions of instrumental vari-
ables (see Methods section in main text), the IVW approach serves as a standard approach
for Mendelian Randomization analysis, which can also be viewed as a meta analysis of sin-
gle causal estimates (Bowden et al., 2015). Let {Gj}Nj=1 be N independent variants which
serve as valid instrumental variables (IVs). For a single variant Gj, the causal effect of
exposure on the outcome can be estimated as βˆj =
Γˆj
γˆj
, where γˆj and Γˆj are the estimated
SNP-exposure and SNP-outcome effects, respectively (Lawlor et al., 2008). Since the vari-
ants are selected to be strongly associated with exposure, the variance of βˆj can be given
as:
σ2Yj
γˆ2j
, where the estimation errors σ2Xj are ignored.
Therefore, the IVW estimator based on the N IVs is given as,
βˆIV W =
∑N
j=1 Γˆj γˆjσ
−2
Yj∑N
j=1 γˆ
2
jσ
−2
Yj
. (49)
In fact, this can be obtained by solving the following weighted least square problem where
σ−2Yj , j = 1, · · · , N are the weights,
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βˆIV W = arg min
β
N∑
j=1
(Γˆj − βγˆj)2
σ2Yj
. (50)
Then the standard error of βˆIV W is given as,
SE(βˆIV W ) =
√
σˆ2∑N
j=1 γˆ
2
jσ
−2
Yj
. (51)
where σˆ2 is the variance of residuals from the weighed regression.
The Egger method extends the IVW method by introducing an intercept term β0 to
address the influence of horizontal pleiotropy (Bowden et al., 2015),
βˆEgger = arg min
β
N∑
j=1
(Γˆj − β0 − βγˆj)2
σ2Yj
. (52)
Then the standard error of the Egger estimate can be obtained by
SE(βˆEgger) =
√
σˆ2∑N
j=1(γˆj − ¯ˆγw)2σ2Yj
. (53)
where ¯ˆγw is the weighted average of the estimated exposure effects that ¯ˆγw =
∑N
i=1 γˆjσ
−2
Yj∑N
i=1 σ
−2
Yj
.
From the model assumption of Egger, we can see that Egger may not have a satisfactory
performance in the presence of weak but non-constant pleiotropic effects. In addition, Egger
may not be robust if there exist a few strong pleiotropic effects (i.e., outliers).
Unlike Egger, GSMR introduces an outlier detection procedure (called HEIDI-outlier)
to reduce the strong effects of horizontal pleiotropy. It further takes into account the
measurement error of the SNP-exposure effect and weak LD between SNPs (Zhu et al.,
2018). Let βˆ = (βˆ1, βˆ2, · · · , βˆN) be the vector of single variant MR estimates and U
be the variance covariance matrix of βˆ, then we have βˆ ∼ N(β1,U). Notice that, if
variants are correlated, the non-diagonal elements in matrix U is non zero. The generalized
least square approach is then applied to estimate the causal effect, yielding βˆGSMR =
(1TU−11)−11TU−1βˆ. In the special case that uncorrelated and strong variants are used as
IVs (now U is a diagonal matrix), the GSMR estimator can be written as follows:
βˆGSMR = arg min
β
N∑
j=1
(Γˆj − βγj)2
σ2Y j + βˆ
2
jσ
2
Xj
, (54)
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Then the corresponding standard error is
SE(βˆGSMR) =
1∑N
j=1 γˆ
2
j /(σ
2
Yj
+ βˆ2jσ
2
Xj
)
. (55)
To deal with horizontal pleiotropy, the HEIDI-outlier method firstly chooses a variant
as the target, and then tests the estimated causal effect of the target variant and each
of other variants. The variants that are significantly different from the target variant
will be considered as outliers and then be removed in model fitting (54, 55). To avoid
choosing a potential pleiotropic outlier as the target variant, the HEIDI-outlier method
adopts an ad-hoc way: it chooses the top exposure-associated variant among those with
the corresponding causal effect estimates in the third quintile (41% to 60%) of the single
causal variant estimates (βˆ1, · · · , βˆN). The HEIDI-outlier method has the risk of selecting
an impropriate variant as the target variant leading to biased estimate or inflated type I
errors.
RAPS uses a random effects model to model the weak Horizontal pleiotropy that αj ∼
N(0, τ 2) with a variance component τ 2 and the measurement error of γˆj is also taken into
account:
Γˆj ∼ N(βγj, τ 2 + σ2Yj), γˆj ∼ N(γj, σ2Xj). (56)
Parameter estimation of RAPS is obtained by maximizing the profile likelihood and
in which γ1, . . . , γN are considered as nuisance parameters being profiled out. The profile
likelihood function is given as follows:
l(β, τ) = −1
2
N∑
j=1
(Γˆj − βγj)2
σ2Yj + τ
2 + β2σ2Xj
+ log(σ2Yj + τ
2). (57)
An adjusted profile score (APS) (McCullagh and Tibshirani, 1990) is used in RAPS to
obtain an consistent estimator of β and τ . To reduce the influence of the large pleiotropic
effects ( i.e. outliers) , robust loss functions, like the Huber loss and Tukey’s biweight loss
functions, are suggested to replace the l2 loss in (57).
Clearly, if we set τ = 0 , the optimum obtained by maximizing (57) w.r.t. β equals
to an IVW estimate with weights: w(β) = 1/(σ2Yj + β
2σ2Xj), which is a function of the
true causal effect β. From this perspective, the estimates from IVW (50) and Egger (52)
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estimates correspond to setting σXj = 0 in w(β), while the estimates from GSMR (54) are
obtained by replacing the unknown true effect size β with βˆj.
Compared with RAPS in (57), we conclude that GSMR ignores weak pleiotropic effects
(τ 2 = 0) which could lead to its inflated type I errors, as shown in simulation study and
real data analysis.
D More simulation results
D.1 Summary-level simulations
We simulated summary-level data D = {γˆ, Γˆ,σX ,σY } to test the robustness of BWMR
and its related methods. We first generated Γj and γj in the following five cases:
• Case-1: γj i.i.d∼ N (0, σ2), αj i.i.d∼ N (0, τ 2), Γj = βγj + αj.
• Case-2: γj i.i.d∼ N (0, σ2), αj i.i.d∼ N (0, τ 2),
Γj =
 βγj + αj, j = 1, 2, ..., (N × C),βcγj + αj, j = (N × C + 1), ..., N,
with βc denoting corrupted value of β and C denoting the corresponding corrupted
rate.
• Case-3: γj i.i.d.∼ N (0, σ2), Γj = βγj + αj and
αj
i.i.d.∼
N (0, τ
2), j = 1, 2, ..., (N × C),
N (0, τ 2c ), j = (N × C + 1), ..., N,
with τ 2c denoting corrupted value of τ
2.
• Case-4: γj i.i.d∼ (1 − R)N (0, σ2) + RN (0, 10σ2), αj i.i.d.∼ N (0, τ 2) and Γj = βγj + αj,
where 0 < R < 1.
• Case-5: γj i.i.d∼ N (0, σ2), Γj = βγj + αj and αj i.i.d.∼ τLaplace(r), where Laplace(r)
represents Laplace (double exponential) distribution with the rate r.
With Γj and γj generated above, we simulated Γˆj and γˆj from γˆj|γj ∼ N (γj, σ2Xj),Γˆj|Γj ∼
N (Γj, σ2Yj), where σXj and σYj were i.i.d. from the uniform distribution U [c, d].
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• Summary-level simulation results in Case-1
beta=0.0 beta=0.2 beta=0.5
0.1 0.2 0.3 0.1 0.2 0.3 0.1 0.2 0.3
−0.3
0.0
0.3
0.6
True value of parameter tau
Method BWMR Egger GSMR RAPS
Estimation
Figure 7: Comparison of estimation accuracy of BWMR, Egger, GSMR and RAPS in
Case-1 of the summary-level data simulation. The simulation parameters were varied in
the following range: β ∈ {0.0, 0.2, 0.5}, τ ∈ {0.1, 0.2, 0.3}, σ = 0.8, [c, d] = [0.3, 0.5]. The
results were summarized from 50 replications.
beta=0.0 beta=0.2 beta=0.5
0.6 0.8 1 0.6 0.8 1 0.6 0.8 1
−0.3
0.0
0.3
0.6
True value of parameter sigma
Method BWMR Egger GSMR RAPS
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Figure 8: Comparison of estimation accuracy of BWMR, Egger, GSMR and RAPS in
Case-1 of the summary-level data simulation. The simulation parameters were varied in
the following range: β ∈ {0.0, 0.2, 0.5}, σ ∈ {0.6, 0.8, 1.0}, τ = 0.2, [c, d] = [0.3, 0.5]. The
results were summarized from 50 replications.
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Figure 9: Comparison of type I error control and statistical power of BWMR, Egger, GSMR
and RAPS in Case-1 of the summary-level data simulation. The simulation parameters
were varied in the following range: β ∈ {0.0, 0.1, 0.2, 0.3, 0.4, 0.5}, τ = 0.3, σ = 0.8,
[c, d] = [0.3, 0.5]. We evaluated the empirical type I error rate and power by controlling type
I error rates at the nomial level 0.05. The results were summarized from 500 replications.
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• Summary-level simulation results in Case-2
beta=0.0 beta=0.2 beta=0.5
0.1 0.2 0.3 0.1 0.2 0.3 0.1 0.2 0.3
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Figure 10: Comparison of estimation accuracy of BWMR, Egger, GSMR and RAPS in
Case-2 of the summary-level data simulation. The simulation parameters were varied in
the following range: β ∈ {0.0, 0.2, 0.5}, τ ∈ {0.1, 0.2, 0.3}, σ = 0.8, [c, d] = [0.3, 0.5], βc = 3,
C = 0.2. The results were summarized from 50 replications.
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Figure 11: Comparison of estimation accuracy of BWMR, Egger, GSMR and RAPS in
Case-2 of the summary-level data simulation. The simulation parameters were varied in
the following range: β ∈ {0.0, 0.2, 0.5}, σ ∈ {0.6, 0.8, 1.0}, τ = 0.2, [c, d] = [0.3, 0.5], βc = 3,
C = 0.2. The results were summarized from 50 replications.
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Figure 12: Comparison of estimation accuracy of BWMR, Egger, GSMR and RAPS in
Case-2 of the summary-level data simulation. The simulation parameters were varied in the
following range: β ∈ {0.0, 0.2, 0.5}, C ∈ {0.1, 0.2, 0.3}, τ = 0.2, σ = 0.8, [c, d] = [0.3, 0.5],
βc = 3. The results were summarized from 50 replications.
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Figure 13: Comparison of type I error control and statistical power of BWMR, Egger,
GSMR and RAPS in Case-2 of the summary-level data simulation. The simulation param-
eters were varied in the following range: β ∈ {0.0, 0.1, 0.2, 0.3, 0.4, 0.5}, τ = 0.3, σ = 0.8,
[c, d] = [0.3, 0.5], βc = 3, C = 0.2. We evaluated the empirical type I error rate and power
by controlling type I error rates at the nomial level 0.05. The results were summarized
from 500 replications.
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• Summary-level simulation results in Case-3
beta=0.0 beta=0.2 beta=0.5
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Figure 14: Comparison of estimation accuracy of BWMR, Egger, GSMR and RAPS in
Case-3 of the summary-level data simulation. The simulation parameters were varied in
the following range: β ∈ {0.0, 0.2, 0.5}, τ ∈ {0.1, 0.2, 0.3}, σ = 0.8, [c, d] = [0.3, 0.5], τc = 3,
C = 0.2. The results were summarized from 50 replications.
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Figure 15: Comparison of estimation accuracy of BWMR, Egger, GSMR and RAPS in
Case-3 of the summary-level data simulation. The simulation parameters were varied in
the following range: β ∈ {0.0, 0.2, 0.5}, σ ∈ {0.6, 0.8, 1.0}, τ = 0.2, [c, d] = [0.3, 0.5], τc = 3,
C = 0.2. The results were summarized from 50 replications.
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Figure 16: Comparison of estimation accuracy of BWMR, Egger, GSMR and RAPS in
Case-3 of the summary-level data simulation. The simulation parameters were varied in the
following range: β ∈ {0.0, 0.2, 0.5}, C ∈ {0.1, 0.2, 0.3}, τ = 0.2, σ = 0.8, [c, d] = [0.3, 0.5],
τc = 3. The results were summarized from 50 replications.
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Figure 17: Comparison of type I error control and statistical power of BWMR, Egger,
GSMR and RAPS in Case-3 of the summary-level data simulation. The simulation param-
eters were varied in the following range: β ∈ {0.0, 0.1, 0.2, 0.3, 0.4, 0.5}, τ = 0.3, σ = 0.8,
[c, d] = [0.3, 0.5], τc = 3, C = 0.2. We evaluated the empirical type I error rate and power
by controlling type I error rates at the nomial level 0.05. The results were summarized
from 500 replications.
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• Summary-level simulation results in Case-4
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Figure 18: Comparison of estimation accuracy of BWMR, Egger, GSMR and RAPS in
Case-4 of the summary-level data simulation. The simulation parameters were varied in
the following range: β ∈ {0.0, 0.2, 0.5}, τ ∈ {0.1, 0.2, 0.3}, σ = 0.8, [c, d] = [0.3, 0.5],
R = 0.2. The results were summarized from 50 replications.
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Figure 19: Comparison of estimation accuracy of BWMR, Egger, GSMR and RAPS in
Case-4 of the summary-level data simulation. The simulation parameters were varied in
the following range: β ∈ {0.0, 0.2, 0.5}, σ ∈ {0.6, 0.8, 1.0}, τ = 0.2, [c, d] = [0.3, 0.5],
R = 0.2. The results were summarized from 50 replications.
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Figure 20: Comparison of type I error control and statistical power of BWMR, Egger,
GSMR and RAPS in Case-4 of the summary-level data simulation. The simulation param-
eters were varied in the following range: β ∈ {0.0, 0.1, 0.2, 0.3, 0.4, 0.5}, τ = 0.3, σ = 0.8,
[c, d] = [0.3, 0.5], R = 0.2. We evaluated the empirical type I error rate and power by
controlling type I error rates at the nomial level 0.05. The results were summarized from
500 replications.
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• Summary-level simulation results in Case-5
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Figure 21: Comparison of estimation accuracy of BWMR, Egger, GSMR and RAPS in
Case-5 of the summary-level data simulation. The simulation parameters were varied in
the following range: β ∈ {0.0, 0.2, 0.5}, τ ∈ {0.1, 0.2, 0.3}, σ = 0.8, [c, d] = [0.3, 0.5], r = 1.
The results were summarized from 50 replications.
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Figure 22: Comparison of estimation accuracy of BWMR, Egger, GSMR and RAPS in
Case-5 of the summary-level data simulation. The simulation parameters were varied in
the following range: β ∈ {0.0, 0.2, 0.5}, σ ∈ {0.6, 0.8, 1.0}, τ = 0.2, [c, d] = [0.3, 0.5], r = 1.
The results were summarized from 50 replications.
63
Q−Q plot
Expected (− log10 p−value)
O
bs
er
ve
d 
(−
lo
g 1
0 
p−
va
lu
e)
1
2
3
4
1 2 3 4
GSMR
RAPS
Egger
BWMR
0.00
0.02
0.04
0.06
0.08
BWMR Egger GSMR RAPS
Method
Type I error rate
0.00
0.25
0.50
0.75
1.00
0.1 0.2 0.3 0.4 0.5
Beta
Method BWMR Egger GSMR RAPS
Power
Figure 23: Comparison of type I error control and statistical power of BWMR, Egger,
GSMR and RAPS in Case-5 of the summary-level data simulation. The simulation param-
eters were varied in the following range: β ∈ {0.0, 0.1, 0.2, 0.3, 0.4, 0.5}, τ = 0.3, σ = 0.8,
[c, d] = [0.3, 0.5], r = 1. We evaluated the empirical type I error rate and power by con-
trolling type I error rates at the nomial level 0.05. The results were summarized from 500
replications.
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D.2 Individul-level simulations
• Individual-level simulations discussing the selection bias in MR
sample size=4000 sample size=5000 sample size=6000 sample size=8000
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Egger.u
Egger.b
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RAPS.u
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Estimation
Figure 24: Comparison of BWMR, Egger, GSMR and RAPS in the individual-
level data simulation, with / without selection bias, under the choices of β ∈
{0.0, 0.1, 0.2, 0.3, 0.4, 0.5}, N0 = 10, 000, n1 = n2 ∈ {4, 000, 5, 000, 6, 000, 8, 000}, pi11 =
0.02, pi10 = 0.08, pi01 = 0.08, pi00 = 0.82, SNR1 = SNR2 = 1 : 1, and p-value threshold =
1 × 10−5. Let “.u” denote simulations without selection bias (unbias), let “.b” denote
simulations with selection bias. The results were summarized from 100 replications.
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Figure 25: Comparison of individual-level data simulation with selection bias using different
sample sizes, under the choices of β ∈ {0.0, 0.1, 0.2, 0.3, 0.4, 0.5}, N0 = 10, 000, n1 = n2 ∈
{4, 000, 5, 000, 6, 000, 8, 000}, pi11 = 0.02, pi10 = 0.08, pi01 = 0.08, pi00 = 0.82, SNR1 =
SNR2 = 1 : 1, and p-value threshold = 1 × 10−5. The results were summarized from 100
replications.
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E Real data analysis
E.1 Data sources
Table 1: Supplementary Table for GWAS sources of metabolites
Metabolite # Sample Size Reference
123 Blood metabolits from multiple metabolic pathways up to 24925 (Kettunen et al., 2016)
Fasting glucose up to 122,743 (Dupuis et al., 2010)
Vitamin D levels up to 41,274 (Manousaki et al., 2017)
Serum Urate up to 14,000 (Ko¨ttgen et al., 2013)
Total Cholesterol up to 188,577 (Willer et al., 2013)
Triglycerides up to 188,577 (Willer et al., 2013)
HDL cholesterol up to 188,577 (Willer et al., 2013)
LDL cholesterol up to 188,577 (Willer et al., 2013)
Table 2: Supplementary Table for GWAS sources of complex human traits and diseases
Category Name # Sample Size Reference
Anthropometric Trait Body mass index 339,224 (Locke et al., 2015)
Anthropometric Trait Body fat percentage 100,716 (Lu et al., 2016)
Anthropometric Trait Height 253,288 (Wood et al., 2014)
Anthropometric Trait Hip circumference 224,459 (Shungin et al., 2015)
Anthropometric Trait Waist circumference 224,459 (Shungin et al., 2015)
Anthropometric Trait Waist hip ratio 224,459 (Shungin et al., 2015)
Anthropometric Trait Birth length 28,459 (van der Valk et al., 2015)
Anthropometric Trait Birth weight 153,781 (Horikoshi et al., 2016)
Anthropometric Trait Childhood obesity 13,848 (Bradfield et al., 2012)
Anthropometric Trait Infant head circumference 10,768 (Taal et al., 2012)
Cardiovascular measure Diastolic blood pressure 120,473 (Liu et al., 2016)
Cardiovascular measure Hypertension 120,473 (Liu et al., 2016)
Cardiovascular measure Mean arterial pressure 120,473 (Liu et al., 2016)
Cardiovascular measure Pulse pressure 120,473 (Liu et al., 2016)
Cardiovascular measure Systolic blood pressure 120,473 (Liu et al., 2016)
Cardiovascular measure Coronary artery disease 184,305 (Nikpay et al., 2015)
Cardiovascular measure Heart rate 181,171 (Den Hoed et al., 2013)
Cardiovascular measure Heart rate variability pvRSA 53,174 (Nolte et al., 2017)
Cardiovascular measure Heart rate variability RMSSD 53,174 (Nolte et al., 2017)
Cardiovascular measure Heart rate variability SDNN 53,174 (Nolte et al., 2017)
Cardiovascular measure Peripheral vascular disease 53,991 (Zhu et al., 2018)
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Category Name # Sample Size Reference
Immune system disorder Atopic dermatitis 103,066 (Paternoster et al., 2015)
Immune system disorder Crohn’s disease 20,883 (Liu et al., 2015)
Immune system disorder Inflammary bowel disease 34,652 (Liu et al., 2015)
Immune system disorder Ulcerative colitis 34,652 (Liu et al., 2015)
Immune system disorder Celiac disease 15,283 (Dubois et al., 2010)
Immune system disorder Eczema 40,835 (Paternoster et al., 2015)
Immune system disorder Multiple sclerosis 27,098 (Sawcer et al., 2011)
Immune system disorder Primary biliary cirrhosis 13,239 (Cordell et al., 2015)
Immune system disorder Rheumatoid arthritis 58,284 (Okbay et al., 2016)
Immune system disorder Systemic lupus erythematosus 23,210 (Bentham et al., 2015)
Immune system disorder Type 1 diabetes 14,741 (Censin et al., 2017)
Metabolic Trait Age at menarche 182,416 (Perry et al., 2014)
Metabolic Trait Age at natural menopause 69,360 (Day et al., 2015)
Metabolic Trait Dyslipidemia 53,991 (Zhu et al., 2018)
Metabolic Trait Estimated glomerular filtration rate 111,666 (Li et al., 2017)
Metabolic Trait Fasting insulin 51,750 (Manning et al., 2012)
Metabolic Trait Fasting proinsulin 10,701 (Strawbridge et al., 2011)
Metabolic Trait Glycated haemoglobin levels 123,665 (Wheeler et al., 2017)
Metabolic Trait Gout 69,374 (Ko¨ttgen et al., 2013)
Metabolic Trait Hemoglobin A1c 123,665 (Wheeler et al., 2017)
Metabolic Trait Hemorrhoids 53,991 (Zhu et al., 2018)
Metabolic Trait Iron deficiency 53,991 (Zhu et al., 2018)
Metabolic Trait Type 2 diabetes 69,033 (Morris et al., 2012)
Metabolic Trait Urinary albumin to creatinine ratio 54,450 (Teumer et al., 2016)
Metabolic Trait Varicose veins 53,991 (Zhu et al., 2018)
Neurodegenerative disease Alzheimer’s disease 54,162 (Lambert et al., 2013)
Neurodegenerative disease Amyotrophic lateral sclerosis 36,052 (Benyamin et al., 2017)
Neurodegenerative disease Age related macular degeneration 53,991 (Zhu et al., 2018)
Neurodegenerative disease Parkinson 8,477 (Pankratz et al., 2012)
Other complex trait Asthma 26,475 (Moffatt et al., 2010)
Other complex trait Breast cancer 2,287 (Hunter et al., 2007)
Other complex trait Dermatophytosis 53,991 (Zhu et al., 2018)
Other complex trait Leptin 32,161 (Kilpela¨inen et al., 2016)
Other complex trait Leptin adjusted for BMI 32,161 (Kilpela¨inen et al., 2016)
Other complex trait Osteoarthritis 53,991 (Zhu et al., 2018)
Other complex trait Osteoporosis 53,991 (Zhu et al., 2018)
Psychiatric disorder Angst 18,000 (Otowa et al., 2016)
Psychiatric disorder Bipolar disorder 16,731 (Sklar et al., 2011)
Psychiatric disorder Attention deficit hyperactivity disorder 5,422 *
Psychiatric disorder Autism spectrum disorder 10,763 *
Psychiatric disorder Major depressive disorder 16,610 *
Psychiatric disorder Schizophrenia 17,115 *
Psychiatric disorder Depress 53,991 (Zhu et al., 2018)
*: (Cross-Disorder Group of the Psychiatric Genomics Consortium et al., 2013)
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Category Name # Sample Size Reference
Psychiatric disorder Child aggressive behaviour 18,988 (Pappa et al., 2016)
Psychiatric disorder Anorexia nervosa 14,477 (Duncan et al., 2017)
Psychiatric disorder Loneliness 10,760 (Gao et al., 2017)
Psychiatric disorder Obsessive compulsive disorder 9,995 (Stewart et al., 2013)
Psychiatric disorder Post-traumatic stress disorder 9,954 (Duncan et al., 2017)
Psychiatric disorder Stress 53,991 (Zhu et al., 2018)
Social Trait Alcohol continuous 70,460 (Schumann et al., 2016)
Social Trait Alcohol light heavy 74,711 (Schumann et al., 2016)
Social Trait Cognitive performance 106,736 (Rietveld et al., 2014)
Social Trait Chronotype 127,898 (Jones et al., 2016)
Social Trait Oversleepers 127,573 (Jones et al., 2016)
Social Trait Sleep duration 127,573 (Jones et al., 2016)
Social Trait Undersleepers 127,573 (Jones et al., 2016)
Social Trait Insomnia complaints 113,006 (Hammerschlag et al., 2017)
Social Trait Educational attainment college 95,429 (Rietveld et al., 2013)
Social Trait Educational attainment eduyears 101,069 (Rietveld et al., 2013)
Social Trait Agreeableness 17,375 (De Moor et al., 2012)
Social Trait Conscientiousness 17,375 (De Moor et al., 2012)
Social Trait Extraversion 17,375 (De Moor et al., 2012)
Social Trait Neuroticism 17,375 (De Moor et al., 2012)
Social Trait Openness 17,375 (De Moor et al., 2012)
Social Trait Intelligence 78,308 (Sniekers et al., 2017)
Social Trait Depressive symptoms 161,460 (Okbay et al., 2016)
Social Trait Neuroticism 170,911 (Okbay et al., 2016)
Social Trait Subjective well being 298,420 (Okbay et al., 2016)
Social Trait Age onset 47,961 (Furberg et al., 2010)
Social Trait Cigarette per day 68,028 (Furberg et al., 2010)
Social Trait Ever smoked 74,035 (Furberg et al., 2010)
Social Trait Former smoker 41,969 (Furberg et al., 2010)
E.2 MR implementation
The p-value threshold for selecting IVs was set to be 5× 10−8. The LD clumping was im-
plemented by using PLINK (Purcell et al., 2007) with a r2 threshold of 0.001 and a window
size of 1Mb. Before implementing MR methods, we harmonised the alleles for the exposure
and the outcome by using the R package “TwoSampleMR” (Hemani et al., 2018), and stan-
darded the SNP-exposure and SNP-outcome effects by using the R package “gsmr” (Zhu
et al., 2018). Egger and RAPS were implemented with the R package “TwoSampleMR”,
GSMR was implemented with its R package “gsmr”, and BWMR was implemented with
our R package “BWMR”.
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E.3 Examination of selection bias
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Figure 26: Comparisons of analysis results provided by RAPS with selection bias (x-axis)
and without selection bias (y-axis). The dots represent estimated causal effect sizes βˆ and
the bars represent their standard errors se(βˆ). The diagonal is indicated by the dashed
line.
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Figure 27: Comparisons of analysis results provided by GSMR with selection bias (x-axis)
and without selection bias (y-axis). The dots represent estimated causal effect sizes βˆ and
the bars represent their standard errors se(βˆ). The diagonal is indicated by the dashed
line.
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Figure 28: Comparisons of analysis results provided by Egger with selection bias (x-axis)
and without selection bias (y-axis). The dots represent estimated causal effect sizes βˆ and
the bars represent their standard errors se(βˆ). The diagonal is indicated by the dashed
line.
E.4 Consistency of analysis results
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Figure 29: Comparisons of analysis results provided by RAPS using Data-A as exposure
data (x-axis) and using Data-B as exposure data (y-axis). The dots represent estimated
causal effect sizes βˆ and the bars represent their standard errors se(βˆ). The diagonal is
indicated by the dashed line.
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Figure 30: Comparisons of analysis results provided by GSMR using Data-A as exposure
data (x-axis) and using Data-B as exposure data (y-axis). The dots represent estimated
causal effect sizes βˆ and the bars represent their standard errors se(βˆ). The diagonal is
indicated by the dashed line.
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Figure 31: Comparisons of analysis results provided by Egger using Data-A as exposure
data (x-axis) and using Data-B as exposure data (y-axis). The dots represent estimated
causal effect sizes βˆ and the bars represent their standard errors se(βˆ). The diagonal is
indicated by the dashed line.
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E.5 Some illustrative examples in real data analysis
• exposure: LDL cholesterol; outcome: height.
Table 3: MR results of “LDL cholesterol - height”
method βˆ sˆe p-value
BWMR -0.0295 0.0164 0.0721
Egger -0.0135 0.0378 0.7222
GSMR -0.0655 0.0088 7.8146×10−14
RAPS -0.0290 0.0169 0.0856
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Figure 32: Comparisons of causal inference results when estimating the causal effect of LDL
cholesterol on height. We use this example to show that GSMR may suffer from inflated
type I error rate when IVs are affected by weak horizontal pleiotropic effects, and the HEIDI
outlier method in GSMR has a risk of selecting an impropriate SNP (e.g., pleiotropic IV)
as the top variant leading to false discovery.
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• exposure: Gp; outcome: Crohn’s disease.
Table 4: MR results of “Gp - Crohn’s disease”
method βˆ sˆe p-value
BWMR 0.0711 0.0678 0.2946
Egger -0.0781 0.1668 0.6521
GSMR 0.1483 0.0417 0.0004
RAPS 0.0691 0.0700 0.3242
−0.05
0.00
0.05
0.10
−0.2 0.0 0.2 0.4
SNP−exposure effect
SN
P−
ou
tc
om
e 
ef
fe
ct
0.9980
0.9985
0.9990
0.9995
w
BWMR result
−0.05
0.00
0.05
0.10
−0.2 0.0 0.2 0.4
SNP−exposure effect
SN
P−
ou
tc
om
e 
ef
fe
ct
Egger result
−0.05
0.00
0.05
0.10
−0.2 0.0 0.2 0.4
SNP−exposure effect
SN
P−
ou
tc
om
e 
ef
fe
ct
Group IV
GSMR result
−0.05
0.00
0.05
0.10
−0.2 0.0 0.2 0.4
SNP−exposure effect
SN
P−
ou
tc
om
e 
ef
fe
ct
RAPS result
Figure 33: Comparisons of causal inference results when estimating the causal effect of Gp
on Crohn’s disease. We use this example to show that GSMR may suffer from inflated type
I error rate when IVs are affected by weak horizontal pleiotropic effects, leading to false
discovery.
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• exposure: waist circumference; outcome: L.LDL.L.
Table 5: MR results of “waist circumference - L.LDL.L”
method βˆ sˆe p-value
BWMR -0.005 0.0632 0.9334
Egger 0.2431 0.2574 0.3482
GSMR 0.0002 0.0587 0.9968
RAPS 0.0004 0.0625 0.9461
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Figure 34: Comparisons of causal inference results when estimating the causal effect of
waist circumference on L.LDL.L. We use this example to show that Egger is sensitive to
outliers due to a few large pleiotropic effects.
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• exposure: age at menarche; outcome: S.VLDL.C.
Table 6: MR results of “age at menarche - S.VLDL.C”
method βˆ sˆe p-value
BWMR -0.0163 0.0463 0.7251
Egger -0.6315 0.1917 0.0015
GSMR -0.0155 0.0436 0.7212
RAPS -0.0069 0.0472 0.8838
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Figure 35: Comparisons of causal inference results when estimating the causal effect of
age at menarche on S.VLDL.C. We use this example to show that Egger may mistakenly
detect pleiotropic IVs or outliers, leading to biased estimates. Indeed, the two components
in summary statistics are due to the phenomenon of selection bias.
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• exposure: CAD; outcome: M.LDL.C.
Table 7: MR results of “CAD - M.LDL.C”
method βˆ sˆe p-value
BWMR 0.0668 0.0978 0.4946
Egger 0.5445 0.5994 0.3690
GSMR -0.0393 0.0647 0.5433
RAPS 0.3317 0.1734 0.0557
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Figure 36: Comparisons of causal inference results when estimating the causal effect of CAD
on M.LDL.C. We use this example to show that RAPS may not be robust to pleiotropic
IVs when the horizontal pleiotropic effects have correlation with SNP-exposure effects.
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E.6 MR-based causal inference between metabolites and complex traits
• Detailed results from BWMR
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Figure 37: Causal effects of 130 metabolites (exposures) on 92 complex human traits (out-
comes) estimated by method BWMR. We selected SNPs as IVs by the p-value threshold
5× 10−8. The symbol ”***” means the p-value is significant after Bonferroni correction at
level 0.05.
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Figure 38: Causal effects of 92 complex human traits (exposures) on 130 metabolites and
the trait dyslipidemia (outcomes) estimated by method BWMR. We selected SNPs as IVs
by the p-value threshold 5× 10−8. The symbol ”***” means the p-value is significant after
Bonferroni correction at level 0.05.
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Figure 39: Significant causal effects of metabolites on complex human traits estimated by
BWMR. We selected SNPs as IVs by the p-value threshold 5 × 10−8 and controlled the
type I error rate after Bonferroni correction at level 0.05.
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Figure 40: Significant causal effects of complex human traits on metabolites estimated by
BWMR. We selected SNPs as IVs by the p-value threshold 5 × 10−8 and controlled the
type I error rate after Bonferroni correction at level 0.05.
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Figure 41: Significant causal effects of metabolites on complex human traits estimated by
RAPS. We selected SNPs as IVs by the p-value threshold 5× 10−8 and controlled the type
I error rate after Bonferroni correction at level 0.05.
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Figure 42: Significant causal effects of complex human traits on metabolites estimated by
RAPS. We selected SNPs as IVs by the p-value threshold 5× 10−8 and controlled the type
I error rate after Bonferroni correction at level 0.05.
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Figure 43: Numerical unstability of RAPS. We implemented the method RAPS to estimate
the causal effects of metabolites on human traits. To test the stability of the method, we
repeated 300 times for each pair of exposure and outcome. The plot shows the cases that
esimations from RAPS are not the same (maximum value − minimum value > 50).
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Figure 44: Numerical unstability of RAPS. We implemented the method RAPS to estimate
the causal effects of metabolites on human traits. To test the stability of the method, we
repeated 300 times for each pair of exposure and outcome. The plot shows the cases that
esimations from RAPS are not the same (2 < maximum value − minimum value < 50).
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Figure 45: Numerical unstability of RAPS. We implemented the method RAPS to estimate
the causal effects of metabolites on human traits. To test the stability of the method, we
repeated 300 times for each pair of exposure and outcome. The plot shows the cases that
esimations from RAPS are not the same (0.01 < maximum value − minimum value < 2).
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Figure 46: Significant causal effects of metabolites on complex human traits estimated by
GSMR. We selected SNPs as IVs by the p-value threshold 5×10−8 and controlled the type
I error rate after Bonferroni correction at level 0.05.
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Figure 47: Significant causal effects of complex human traits on metabolites estimated by
GSMR. We selected SNPs as IVs by the p-value threshold 5×10−8 and controlled the type
I error rate after Bonferroni correction at level 0.05.
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• Detailed results from Egger
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Figure 48: Significant causal effects of metabolites on complex human traits estimated by
Egger. We selected SNPs as IVs by the p-value threshold 5× 10−8 and controlled the type
I error rate after Bonferroni correction at level 0.05.
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Figure 49: Significant causal effects of complex human traits on metabolites estimated by
Egger. We selected SNPs as IVs by the p-value threshold 5× 10−8 and controlled the type
I error rate after Bonferroni correction at level 0.05.
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